Gefitinib (ZD1839)

Name: Gefitinib (ZD1839)
Brand: Selleck Chemicals
SKU: S1025
Rating: 5 (287 reviews)

For research use only. Not for use in humans.

Catalog No.S1025

287 publications

Molecular Weight(MW): 446.90

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Selleck's Gefitinib (ZD1839) has been cited by 287 publications

Cancer Discov, 2019, 9(7):926-943

PubMed: 31092401 ( click the link to review the publication )

Cell Stem Cell, 2019, 25(1):69-86

PubMed: 31080136 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Med, 2018, 24(4):512-517

PubMed: 29505033 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):427-438

PubMed: 30205045 ( click the link to review the publication )

Nature, 2017, 547(7664):453-457

PubMed: 28678785 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Nature, 2014, 508(7494):118-22

PubMed: 24670642 ( click the link to review the publication )

Nat Med, 2013, 19(11):1469-1472

PubMed: 24162815 ( click the link to review the publication )

Nature, 2012, 483(7387):100-3

PubMed: 22281684 ( click the link to review the publication )

Cell, 2012, 151(5):937-50

PubMed: 23178117 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Nat Microbiol, 2019, 4(2):216-225

PubMed: 30420785 ( click the link to review the publication )

Mol Cell, 2019, 73(1):166-182

PubMed: 30609389 ( click the link to review the publication )

Hepatology, 2019, 10.1002/hep.30780

PubMed: 31127639 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

Nano Lett, 2019, 19(10):7526-7533

PubMed: 31487192 ( click the link to review the publication )
Nat Commun, 2019, 10(1):2919

PubMed: 31266962 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1660545

PubMed: 31462148 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1660545

PubMed: 31462148 ( click the link to review the publication )

EMBO J, 2019, 38(4)

PubMed: 30643021 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )

Cancer Res, 2019, 79(4):819-829

PubMed: 30573522 ( click the link to review the publication )

J Am Soc Nephrol, 2019, 30(8):1454-1470

PubMed: 31253651 ( click the link to review the publication )

Matrix Biol, 2019, 10.1016/j.matbio.2019.07.006

PubMed: 31323325 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

Int J Cancer, 2019, 145(5):1432-1444

PubMed: 30784054 ( click the link to review the publication )

Oncogene, 2019, 38(11):1936-1950

PubMed: 30390071 ( click the link to review the publication )

Oncogene, 2019, 38(37):6399-6413

PubMed: 31324888 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):46

PubMed: 30709379 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):96

PubMed: 30791926 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)

PubMed: 30609749 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31635301 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):77

PubMed: 31262335 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):283

PubMed: 30911072 ( click the link to review the publication )

Signal Transduct Target Ther, 2019, 4:25

PubMed: 31637005 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Cell Physiol Biochem, 2019, 53(5):805-819

PubMed: 31670920 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0181

PubMed: 31501278 ( click the link to review the publication )
Cell Prolif, 2019, 52(6):e12680

PubMed: 31454111 ( click the link to review the publication )

Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )

Lung Cancer, 2019, 137:85-93

PubMed: 31563735 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(3):606-617

PubMed: 31565489 ( click the link to review the publication )

Artif Cells Nanomed Biotechnol, 2019, 47(1):3231-3238

PubMed: 31373232 ( click the link to review the publication )

DNA Repair (Amst), 2019, 78:37-44

PubMed: 30954901 ( click the link to review the publication )

Front Oncol, 2019, 9:1167

PubMed: 31750252 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31546690 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4488-4497

PubMed: 30679314 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:117

PubMed: 31073278 ( click the link to review the publication )

Mol Carcinog, 2019, 10.1002/mc.23139

PubMed: 31777985 ( click the link to review the publication )

Front Pharmacol, 2019, 10:1116

PubMed: 31649529 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Respir Res, 2019, 20(1):164

PubMed: 31331328 ( click the link to review the publication )

Biomed Pharmacother, 2019, 118:109169

PubMed: 31310954 ( click the link to review the publication )

J Proteomics, 2019, 195:114-124

PubMed: 30660770 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(10)

PubMed: 31121829 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):527-536

PubMed: 30535494 ( click the link to review the publication )

Life Sci, 2019, 224:23-32

PubMed: 30902544 ( click the link to review the publication )

J Drug Target, 2019, 27(4):451-459

PubMed: 30381967 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 106:96-106

PubMed: 30471423 ( click the link to review the publication )
Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Transl Oncol, 2019, 12(11):1516-1524

PubMed: 31450127 ( click the link to review the publication )

Eur J Pharmacol, 2019, 855:10-19

PubMed: 31028739 ( click the link to review the publication )

Eur J Pharmacol, 2019, 850:97-108

PubMed: 30753867 ( click the link to review the publication )

Eur J Pharmacol, 2019, 856:172409

PubMed: 31132355 ( click the link to review the publication )

Biosci Rep, 2019, 39(8)

PubMed: 31316001 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:6033-6043

PubMed: 31440060 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:3129748

PubMed: 31346515 ( click the link to review the publication )

Oncol Lett, 2019, 18(5):5621-5627

PubMed: 31620204 ( click the link to review the publication )

Oncol Lett, 2019, 18(1):368-374

PubMed: 31289508 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3785-3793

PubMed: 31262905 ( click the link to review the publication )

Exp Ther Med, 2019, 17(1):953-959

PubMed: 30651886 ( click the link to review the publication )

Oncotarget, 2019, 10(11):1171-1192

PubMed: 30838090 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )

Oncotarget, 2019, 10(26):2546-2560

PubMed: 31069016 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4728

PubMed: 30413706 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(3)

PubMed: 29449326 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3097-3107

PubMed: 29506987 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3928-3940

PubMed: 29685880 ( click the link to review the publication )

Theranostics, 2018, 8(5):1256-1269

PubMed: 29507618 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):109

PubMed: 30157900 ( click the link to review the publication )
Oncogene, 2018, 37(12):1576-1593

PubMed: 29326440 ( click the link to review the publication )

Cancer Lett, 2018, 424:84-96

PubMed: 29524558 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

Cancers (Basel), 2018, 10(6)

PubMed: 29925812 ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201800011R

PubMed: 29812969 ( click the link to review the publication )

Exp Mol Med, 2018, 50(1):e435

PubMed: 29371698 ( click the link to review the publication )

Exp Mol Med, 2018, 50(4):52

PubMed: 29700289 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 51(1):337-355

PubMed: 30453282 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):77

PubMed: 30409180 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(10):1892-1908

PubMed: 29970458 ( click the link to review the publication )

Eur J Med Chem, 2018, 144:330-348

PubMed: 29275232 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1458-1469

PubMed: 29934325 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(7):1185-1195

PubMed: 29724813 ( click the link to review the publication )

J Immunol, 2018, 200(8):2809-2818

PubMed: 29531172 ( click the link to review the publication )

Biochem Pharmacol, 2018, 152:327-337

PubMed: 29660315 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

J Biol Chem, 2018, 293(35):13401-13414

PubMed: 29997256 ( click the link to review the publication )

Respir Res, 2018, 19(1):96

PubMed: 29784046 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:5785-5798

PubMed: 30510448 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:6695-6703

PubMed: 30584364 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):50

PubMed: 30053908 ( click the link to review the publication )
Phytomedicine, 2018, 39:33-41

PubMed: 29433681 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2143-2154

PubMed: 29620166 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(10):921-933

PubMed: 29856687 ( click the link to review the publication )

Cell Cycle, 2018, 17(23):2577-2592

PubMed: 30488756 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2171-2182

PubMed: 30106444 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):1937-1946

PubMed: 30106446 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):775-782

PubMed: 29901173 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8455-8463

PubMed: 30555238 ( click the link to review the publication )

J Ovarian Res, 2018, 11(1):12

PubMed: 29402301 ( click the link to review the publication )

Mol Med Rep, 2018, 18(4):3882-3890

PubMed: 30106133 ( click the link to review the publication )

Oncol Lett, 2018, 15(3):2829-2838

PubMed: 29467862 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(26):18254-18268

PubMed: 29719603 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(42):E9869-E9878

PubMed: 30275324 ( click the link to review the publication )

Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Autophagy, 2017, 13(7):1093-1112

PubMed: 28513279 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(15):E3129-E3138

PubMed: 28351972 ( click the link to review the publication )

Genes Dev, 2017, 31(17):1754-1769

PubMed: 28982759 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3551-3563

PubMed: 28428274 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

Mol Cancer, 2017, 16(1):34

PubMed: 28158983 ( click the link to review the publication )

Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )
ACS Photonics, 2017, 5(2):487-494

PubMed: 29805987 ( click the link to review the publication )

Oncogene, 2017, 36(48):6691-6700

PubMed: 28745317 ( click the link to review the publication )

J Med Chem, 2017, 60(17):7447-7458

PubMed: 28787156 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(11):1501-1511

PubMed: 29022575 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

Eur J Pharmacol, 2017, 821:21-28

PubMed: 29277715 ( click the link to review the publication )

Oncol Rep, 2017, 37(2):1212-1218

PubMed: 27959426 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 493(1):213-219

PubMed: 28899783 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 482(4):1334-1340

PubMed: 27939888 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

Oncotarget, 2017, 8(70):115620-115631

PubMed: 29383186 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

J Clin Invest, 2016, 126(9):3296-312

PubMed: 27482886 ( click the link to review the publication )

Nat Commun, 2016, 7:12231

PubMed: 27456471 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(21):5370-5382

PubMed: 27178741 ( click the link to review the publication )

EMBO Rep, 2016, 17(5):724-38

PubMed: 27013495 ( click the link to review the publication )
J Pathol, 2016, 239(3):320-34

PubMed: 27102572 ( click the link to review the publication )

Acta Neuropathol Commun, 2016, 4(1):96

PubMed: 27586084 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

Oral Oncol, 2016, 59:12-19

PubMed: 27424178 ( click the link to review the publication )

Oral Oncol, 2016, 56:62-70

PubMed: 27086488 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 10.1016/j.bbagen.2016.05.011

PubMed: 27180173 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1859(11):1449-1458

PubMed: 27412911 ( click the link to review the publication )

Clin Lung Cancer, 2016, 17(4):263-270

PubMed: 26707383 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Int J Oncol, 2016, 49(4):1427-36

PubMed: 27498706 ( click the link to review the publication )

Int J Oncol, 2016, 48(3):937-44

PubMed: 26783187 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):194-200

PubMed: 27180268 ( click the link to review the publication )

Eur J Pharmacol, 2016, 789:458-467

PubMed: 27514773 ( click the link to review the publication )

Oncol Rep, 2016, 36(2):729-36

PubMed: 27373987 ( click the link to review the publication )

Neurosurg Focus, 2016, 41(6):E14

PubMed: 27903123 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0163149

PubMed: 27643613 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Oncotarget, 2016, 7(32):52392-52403

PubMed: 27447558 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Nat Commun, 2015, 6:6377

PubMed: 25758528 ( click the link to review the publication )

Nat Commun, 2015, 6:6240

PubMed: 25670642 ( click the link to review the publication )

J Thorac Oncol, 2015, 10.1097/JTO.0000000000000500

PubMed: 25658629 ( click the link to review the publication )
Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.04.049

PubMed: 26027934 ( click the link to review the publication )

Cancer Lett, 2015, 369(1):103-11

PubMed: 26297988 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10-:2238-48

PubMed: 26208525 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 10.1074/mcp.M115.049783 mcp.M115.049783.

PubMed: 25953087 ( click the link to review the publication )

Lung Cancer, 2015, 88(1):16-23

PubMed: 25704955 ( click the link to review the publication )

J Biol Chem, 2015, 290(41):24784-92

PubMed: 26304118 ( click the link to review the publication )

J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed: ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )

Int J Oncol, 2015, 46(3):1214-24

PubMed: 25530180 ( click the link to review the publication )

Oncol Rep, 2015, 33(4):1860-6

PubMed: 25634113 ( click the link to review the publication )

Oncol Rep, 2015, 34(3):1613-9

PubMed: 26166014 ( click the link to review the publication )

Oncol Rep, 2015, 34(4):1875-82

PubMed: 26238612 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2795-803

PubMed: 25964559 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2015, 10.1016/j.ijrobp.2015.01.026

PubMed: 25823448 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Sci Transl Med, 2014, 6(219):219ra9

PubMed: 24431113 ( click the link to review the publication )

Mol Cell, 2014, 55(6):904-15

PubMed: 25219500 ( click the link to review the publication )

Cancer Res, 2014, 74(1):253-62

PubMed: 24165158 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )
Int J Cancer, 2014, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Oncogene, 2014, 33(19):2495-503

PubMed: 23728339 ( click the link to review the publication )

Oncogene, 2014, 33(35):4385-95

PubMed: 24096476 ( click the link to review the publication )

MBio, 2014, 5(4):e01340-14

PubMed: 25096879 ( click the link to review the publication )

Cancer Lett, 2014, 342(1):82-91

PubMed: 24001610 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Cell Oncol , 2014, 37(5):377-86

PubMed: 25228008 ( click the link to review the publication )

Lung Cancer, 2014, 85(2):141-6

PubMed: 24957682 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

Colloids and Surfaces B: Biointerfaces, 2014, 123:61-7

PubMed: 25216919 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(3):318-22

PubMed: 24335466 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Int J Oncol, 2014, 45(1):393-400

PubMed: 24819550 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: ( click the link to review the publication )

Am J Physiol Renal Physiol, 2014, 307(4):F435-44

PubMed: 24990892 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 74(3):511-20

PubMed: 25038613 ( click the link to review the publication )

PLoS One, 2014, 9(4):e93651

PubMed: 24695557 ( click the link to review the publication )

PLoS One, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Horm Cancer, 2014, 289(24):17195-202

PubMed: 24778185 ( click the link to review the publication )

Exp Mol Pathol, 2014, 97(1):154-165

PubMed: 24984270 ( click the link to review the publication )
Langenbecks Arch Surg, 2014, 10.1007/s00423-014-1235-1

PubMed: 25070024 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2014, 88(4):947-54

PubMed: 24606853 ( click the link to review the publication )

University of Alberta, 2014, Yahya Muhammad Fiteih

PubMed: ( click the link to review the publication )

Guangxi Medical University, 2014, Suning Huang

PubMed: ( click the link to review the publication )

JBUON , 2014, 19(2): 466-473

PubMed: ( click the link to review the publication )

Ann Oncol, 2013, 24(2):362-9

PubMed: 22967992 ( click the link to review the publication )

J Clin Endocrinol Metab, 2013, 98(6):2502-12

PubMed: 23559083 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(2):444-53

PubMed: 24258346 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(11):2541-58

PubMed: 24026012 ( click the link to review the publication )

Mol Oncol, 2013, 7(1):121-9

PubMed: 23127547 ( click the link to review the publication )

Carcinogenesis, 2013, 34(9):1994-9

PubMed: 23677069 ( click the link to review the publication )

Cell Prolif, 2013, 46(4):447-56

PubMed: 23829318 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):473-8

PubMed: 23891090 ( click the link to review the publication )

J Biol Chem, 2013, 288(48):34930-42

PubMed: 24142702 ( click the link to review the publication )

Drug Metab Dispos, 2013, 10.1124/dmd.113.054189

PubMed: 24335466 ( click the link to review the publication )

Prostate, 2013, 73(13):1453-61

PubMed: 23765757 ( click the link to review the publication )

PLoS One, 2013, 8(12):e81393

PubMed: 24339922 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82625

PubMed: 24349321 ( click the link to review the publication )

Exp Mol Pathol, 2013, 94(2):386-97

PubMed: 23399805 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

J Genet Syndr Gene Ther, 2013, 4

PubMed: 25520884 ( click the link to review the publication )

Herpesviridae, 2013, 4(1):1

PubMed: 23342981 ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )
Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):1908-16

PubMed: 22722337 ( click the link to review the publication )

Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806 ( click the link to review the publication )

Oncogene, 2012, 32(34):4034-42

PubMed: 22964644 ( click the link to review the publication )

Cancer Lett, 2012, 321(2):187-94

PubMed: 22343320 ( click the link to review the publication )

Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556 ( click the link to review the publication )

Biochem Pharmacol, 2012, 84(4):425-31

PubMed: 22634404 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896 ( click the link to review the publication )

Int J Oncol, 2012, 41(3):869-75

PubMed: 22752005 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51549

PubMed: 23272116 ( click the link to review the publication )

Oncotarget, 2012, 2(12):1134-44

PubMed: 22193779 ( click the link to review the publication )

Mol Syst Biol, 2011, 7:486

PubMed: 21525872 ( click the link to review the publication )

Oncogene, 2011, 30(6):737-50

PubMed: 20890302 ( click the link to review the publication )

Antivir Res, 2011, 89(1):64-70

PubMed: 21094187 ( click the link to review the publication )

J Immunother, 2011, 34(4):372-81

PubMed: 21499124 ( click the link to review the publication )

Mol Biosyst, 2011, 7(12):3223-33

PubMed: 21956701 ( click the link to review the publication )

Exp Mol Pathol, 2011, 91(1):400-10

PubMed: 21565184 ( click the link to review the publication )

Vet Comp Oncol, 2011, 11(2):124-39

PubMed: 22235915 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Features

A potent EGFR tyrosine kinase inhibitor.

Targets

Tyr1173 (NR6W cells) ^[1]	Tyr1173 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6W cells) ^[1]
26 nM	37 nM	37 nM	57 nM

In vitro

Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell lines. The phosphorylation sites Tyr1173 and Tyr992 are less sensitive requiring higher concentrations of Gefitinib for inhibition. Gefitinib effectively blocks the phosphorylation of PLC-γ, with IC50 of 27nM, in NR6W cells. The NR6wtEGFR and NR6M cell lines has low levels of PLC-γ phosphorylation but the level in the NR6M cell line is more resistant to inhibition by Gefitinib with IC50 of 43 nM and 369 nM, respectively. Gefitinib inhibits Akt phosphorylations, with IC50 of 220 and 263nM, in the low-EGFR- and -EGFRvIII-expressing cell lines, respectively. Gefitinib in the dose range from 0.1 to 0.5μM significantly facilitates, rather than abrogates, colony formation of NR6M cells. However, at a concentration of 2 μM Gefitinib completely blocks NR6M colony formation. Gefitinib rapidly and in a dose-dependent manner inhibits EGFR and ERK phosphorylation up to 72 hours after EGF stimulation in both the high- and low-EGFR-expressing cell lines. ^[1] Gefitinib is the monolayer growth of these EGF-driven untransformed MCF10A cells with an IC50 of 20 nM. ^[2] The combination of Gefitinib (0.2 μM and 0.5 μM) with irradiation lead to a significant growth inhibition in LoVo cells, compared with radiation alone.. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
KB	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4WzRWlEPTB;MD6wOVQh\|ryP	NXLSe\|dDOTZ3MU[0O\|M>
NIH3T3	M1\yXmZ2dmO2aX;uJGF{e2G7	NVHJUXVxOC5{IN88US=>	M4H0[VIhcA>?	MmHRSG1UVw>?	Ml7GTY5pcWKrdHnvckBw\iCHR1[gd5RqdXWuYYTl[EBpfW2jbjDldoJDOSCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjBzNESg{txO	M4rYXlE3PDhyMki0
COS7	Ml7HSpVv[3Srb36gRZN{[Xl?	NYnJZYhNQTZizszN			NGK2WWVKdmirYnn0bY9vKG:oIHj1cYFvKEqDS{KgWlYyP0ZibYX0ZY51KGW6cILld5Nm\A>?	M4PYcFE4OTd6N{Ky
A549	MoSwR5l1d3SxeHnjJGF{e2G7		NXuzeYt[QTZiaB?=	NHTjVZBFVVOR	M3viNWlEPTB;MUOuOVkh\|ryP	MUKxPFMyOzhyNx?=
K562	MXXDfZRwfG:6aXOgRZN{[Xl?		NUnFeItTQTZiaB?=	NUPadndWTE2VTx?=	Mn74TWM2OD17LkO2JO69VQ>?	M{Pic\|E5OzF\|OEC3
MDA-MB-231	M2rIOmN6fG:2b4jpZ{BCe3OjeR?=		NF3XNos6PiCq	M3Psd2ROW09?	M3jRRWlEPTB;M{[uOlEh\|ryP	M4XjOFE5OzF\|OEC3
MOLT4	M12wRWN6fG:2b4jpZ{BCe3OjeR?=		NF;BS2Q6PiCq	NWm2eVRuTE2VTx?=	NUDhSYNlUUN3ME2xOU4xOiEQvF2=	NEfSPHAyQDNzM{iwOy=>
MCF7	NFHLN3ZEgXSxdH;4bYMhSXO\|YYm=	NYPUWHhTPTBizszN	NHnIeXU4OiCq		NYDGflhQUUN3ME2xNk4xPSEQvF2=	M3rQ[VE5PzdzOEG5
BT474	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlzpO\|IhcA>?		M2fX[WFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQmS0O\|Qh[2WubIOgc5ZmemW6cILld5NqdmdiRWLCZlIhf2m2aDDFR\|UxKG:oIECuN{DPxE1?	NVfO[ZV7OTlyMki0NlQ>
HN5	M2XyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFTabFE4OiCq		MUfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiQNTDj[YxteyCxdnXy[ZhxemW\|c3nu[{BGT0[UIIfpeIghTUN3MDDv[kAxNjBzIN88US=>	M4fxV\|E6ODJ6NEK0
BA/F3	NVHqSG9lS3m2b4TvfIlkKEG\|c3H5		MYO3NkBp		NGXOb4tEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFXHSnIhVDh3OGKgcZV1[W62IIfpeIghUUN3MDDv[kAxNjBzMEig{txO	Mn23NVkzOzl{Mkm=
NIH3T3	M2O1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX;2RlBuPzJiaB?=		NYjhUpNVT3Kxd4ToJIlvcGmkaYTpc44hd2ZibX;1d4UhVkmKL{PUN{Bk\WyuczDlfJBz\XO\|aX7nJIVzSjJiZ3Xu[UB4cXSqIFnDOVAhd2ZiMD61OEDPxE1?	MofmNVk3PjV\|N{e=
MCF7 MX	MVLGeY5kfGmxbjDBd5NigQ>?		NHToS\|Q{OCCvaX6=		MnXiTY5pcWKrdHnvckBw\iCEQ2LQJIV5eHKnc4Pl[EB4cXSqIFnDOVAhd2ZiMT6xJO69VQ>?	MoHqNVk6OzJ7NkC=
A431	NELkU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFq1NHMyOCEQvF2=	M3HMSlczKGh?		NX7aS45rT0l3ME2wMlUyPCEQvF2=	M1\1clE6QTZ7NE[1
A431	MmjBT4lv[XOnIFHzd4F6	NID5OZAxNjFizszN	NVjQ[pdSOSCq		MVPJcohq[mm2aX;uJI9nKEWJRj3pcoR2[2WmIFXHSnIheGixc4Doc5J6dGG2aX;u	NGf0V48yQTl4OUS2OS=>
A431	NIi0c4pMcW6jc3WgRZN{[Xl?	NXjZWZlHOTByIN88US=>	MXqxNEBucW5?		MlXXVJJwdG:wZ3XkJIlvcGmkaYTvdpkh[WO2aY\peJkhd2ZiRVfGMYlv\HWlZXSgSWdHWiCyaH;zdIhwenmuYYTpc44>	MomyNVk6Pjl2NkW=
Sf9	MlHuT4lv[XOnIFHzd4F6		MWWxNEBucW5?	NV65TGJ[TE2VTx?=	NW\oemZ1UW6qaXLpeIlwdiCxZjDFS2ZTKGW6cILld5Nm\CCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKnY3XweI9zKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODN\|IN88US=>	M2HrWlIxODV4NEK1
NCI-H1975	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXBOUDPxE1?	M3PwcFczKGh?		Ml\RTWM2OD16LkK2JO69VQ>?	M3TQ[lIxOTVzNkew
NCI-H1975	NWPKXlN7U2mwYYPlJGF{e2G7	NHLDNIwyOCEQvF2=			NE\uNZJKdmirYnn0bY9vKG:oIFXHSnIh[XW2b4Doc5NxcG:{eXzheIlwdg>?	NUTxcHZDOjBzNUG2O\|A>
NCI-H1975	NIr6O3ZHfW6ldHnvckBCe3OjeR?=	NFTZfVUyOCEQvF2=			MkHTTY5pcWKrdHnvckBw\iCHUlLCNkBifXSxcHjvd5Bpd3K7bHH0bY9v	NGHxengzODF3MU[3NC=>
NCI-H1975	M1PqN2Z2dmO2aX;uJGF{e2G7	MlnPOUDPxE1?	M{PUVlQ5KGh?		NHLBXGRKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHHzd4V{e2WmIHHzJIFkfGm4YYTpc44hd2ZiY3HzdIF{\S1\|	NGTId\|UzODF3MU[3NC=>
A375	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{XreFQ5KGh?		MXLJR\|UxRTJyLkW1JO69VQ>?	NV3KVIp{OjB\|MES1N\|c>
SMMC7721	MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3TPRVQ5KGh?		MXzJR\|UxRTN\|LkGyJO69VQ>?	M1zjWVIxOzB2NUO3
DU145	Ml7uR5l1d3SxeHnjJGF{e2G7		M3nXNFUh\A>?	NXP4WIpvTE2VTx?=	NH\hflBKSzVyPUSyMlE4KM7:TR?=	M4O0VlIxPDZ4NUW1
MIAPaCa2	NYPzU4Z5S3m2b4TvfIlkKEG\|c3H5		MW[1JIQ>	NY\rXXA2TE2VTx?=	MlHlTWM2OD13MD62NkDPxE1?	MWKyNFQ3PjV3NR?=
PANC1	MnzSR5l1d3SxeHnjJGF{e2G7		NFeyUFE2KGR?	M4LvXWROW09?	MX3JR\|UxRTRyLkSyJO69VQ>?	MVeyNFQ3PjV3NR?=
PC9	NXvybWdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFXHSnIu\GWoaXPp[Y51KGi3bXHuJHBEQSClZXzsd{B4cXSqIFXDOVAhd2ZiMD6wNVch\|ryP	M13GVVIyOjB6OECy
PC9	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHfyc5d1cC2{ZYPpd5RidnRiaIXtZY4hWEN7IHPlcIx{KGW6cILld5NqdmdiRVfGVkBGPzR4X1G3OVAwXDd7MF2gcZV1[W62IIfpeIghTUN3MDDv[kA4KM7:TR?=	NIrGb4YzOTJyOEiwNi=>
PC3	MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVSxNEDPxE1?	MlfmO\|IhcA>?	MUTEUXNQ	MkTrTWM2OD15LkSg{txO	NFjUcYMzOTN3M{W0Oi=>
MDA-MB-468	M4m0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHmVZVKOTByIN88US=>	MYm0PEBp	NF20SoRFVVOR	NUK3NnhZSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJk>	MlfhNlE1Ojl4M{K=
Plasmodium falciparum					M1XmTpFJXFNicILv[oltcW6pIH\vdkBqdmirYnn0c5J{KG:oIGDsZZNud2SrdX2g[oFt[2myYYL1cUBxem:uaX\ldoF1cW:w	M1i4elIyQDF5MES1
NCI-H1993	M4jlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFv2Z4c4OiCq	Ml\aSG1UVw>?	NXjoUGY2UUN3ME2wMlEh\|ryP	MljaNlE6OTZ2M{O=
NCI-H292	M4rOeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoC2O\|IhcA>?	NFPsN4RFVVOR	NH7F[oFKSzVyPUCuNFIh\|ryP	M1jsUFIyQTF4NEOz
A431	MmfPT4lv[XOnIFHzd4F6		NInqWXczKGh?	NUjqSVluTE2VTx?=	MYjJcohq[mm2aX;uJI9nKEWJRmKgdIhwe3Cqb4L5cIF1cW:wIHnuJGVITi2\|dHnteYxifGWmIHj1cYFvKEF2M{Gge4l1cCCLQ{WwJI9nKDBwMECxJO69VQ>?	NF:xfJYzOjFyMUGzNi=>
MCF7	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrVZ3IyODEEoN88[{9uVA>?	NH7hVFY1QCCq	M3WxTmROW09?	NVm5epFMSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJI93\XKneIDy[ZN{cW6pIFXHSnIh\2WwZTD3bZRpKEmFNUCgc4YhOTJwMEWg{txO	MX2yNlEyQTF\|MB?=
BT474	NGjWdGpEgXSxdH;4bYMhSXO\|YYm=	M2\VTVExKM7:TR?=	MmLPOFghcA>?		NIDjOG1EgXSxdH;4bYNqfHliYXfhbY5{fCC\|ZYL1cU1{fGG{dnXkJIh2dWGwIFLUOFc1KGOnbHzz	MXGyNlE{QDNyOB?=
MCF7	MlfZR5l1d3SxeHnjJGF{e2G7	MmrFNVAh\|ryP	MojnOFghcA>?		NFXZOGhEgXSxdH;4bYNqfHliYXfhbY5{fCC\|ZYL1cU1{fGG{dnXkJIh2dWGwIF3DSlch[2WubIOgc5Zmei2neIDy[ZN{cW6pIFXyZmIzKGOnbHzz	MUiyNlE{QDNyOB?=
HCC827	MVXLbY5ie2ViQYPzZZk>	NFTEXXkxNjF{NTFOwG0>	NHKwW4ozPCCq	MVXEUXNQ	MWjJcohq[mm2aX;uJI9nKEWJRmKg[IVtKEV5NE[tRVc2OCCvdYThcpQhYTFyNkigZZV1d3Cqb4PwbI9zgWyjdHnvci=>	MWGyNlM{QTN2Mh?=
HCC827	MV\LbY5ie2ViQYPzZZk>	M1jzeFAvOTJ3IN88US=>	NF\jSZAzPCCq	NX71[HA3TE2VTx?=	NEj1fHhKdmirYnn0bY9vKG:oIFXHSnIh\GWuIFW3OFYuSTd3MDDteZRidnRvbXXkbYF1\WRiRYLrJJBpd3OyaH;yfYxifGmxbh?=	NVn6d4ZXOjJ\|M{mzOFI>
HCC827	MVvLbY5ie2ViQYPzZZk>	NHrqXIwxNjF{NTFOwG0>	M1HPWFI1KGh?	NGmybllFVVOR	NHfSNm9KdmirYnn0bY9vKG:oIFXHSnIh\GWuIFW3OFYuSTd3MDDteZRidnRvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?=	MkfBNlI{Ozl\|NEK=
A431	MojZT4lv[XOnIFHzd4F6	MmPGNVAxKM7:TR?=	NFfKRmQ{OCCvaX6=		NHzYRVJKdmirYnn0bY9vKG:oIFXHSnIh\GW{aY\l[EBnem:vIHj1cYFvKEF2M{GgZ4VtdCCvZX3idoFv\SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHCxbImtS4x2NVS7cjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFEvODhizszN	M3\vXFIzPjl6N{iy
H460	MXXDfZRwfG:6aXOgRZN{[Xl?		NUDrbnl7PzJiaB?=		NH;GUXJKSzVyPUWuOVkh\|ryP	M4HVe\|IzPzJ5NES5
HT-29	M{T3OWN6fG:2b4jpZ{BCe3OjeR?=		NXrRNpVHPzJiaB?=		NXfhfpdkUUN3ME2zMlM3KM7:TR?=	Mmf4NlI4Ojd2NEm=
SGC7901	MmjJR5l1d3SxeHnjJGF{e2G7		NIr4c\|I4OiCq		M1LpXGlEPTB;MUCuNlYh\|ryP	NF3vUFIzOjd{N{S0PS=>
A498	M3fNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\0WYpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG0PVgh[2WubIOg[ZhxemW\|c3nu[{BGT0[UIHHu[EBUWkNid3n0bEBKSzVyIH;mJFgvPiEQvF2=	NH\0T3QzOjhzOEi0PC=>
Calu3	M1rMNWN6fG:2b4jpZ{BCe3OjeR?=	NYrWdFNTOTBizsznM41N	M{XHVFczKGh?		M2HL[GlEPTB;MT62JO69VQ>?	M1\ydVI{OTF4MU[4
FADU	M33hemN6fG:2b4jpZ{BCe3OjeR?=	Ml3yNVAh\|rypL33M	M1n6OVczKGh?		MmPSTWM2OD1yLkC1JO69VQ>?	MnPtNlMyOTZzNki=
HCC827	NYjhPZlSS3m2b4TvfIlkKEG\|c3H5	NGHiNGUyOCEQvHevcWw>	MW[3NkBp		M3TpW2lEPTB;MD6wNFE2KM7:TR?=	M1PrOFI{OTF4MU[4
PC9	Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGT0VpAyOCEQvHevcWw>	NWfYco5LPzJiaB?=		M13Pe2lEPTB;MD6wNVQh\|ryP	MXmyN\|EyPjF4OB?=
Sf9	MXvLbY5ie2ViQYPzZZk>		MV[xJIg>	MX7EUXNQ	NGWwbWJKdmirYnn0bY9vKG:oIHj1cYFvKEeVVD30ZYdo\WRiRVfGVkBNQDN2UjDteZRidnRiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAxNjBzNTFOwG0>	MnL5NlM3OTF4OUG=
16HBE14o-	NVfq[5FkS3m2b4TvfIlkKEG\|c3H5	NGO4N5QyOCEQvF2=	MVu3NkBp	MWfEUXNQ	NYS0Z2JYS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hOT[KQlWxOI8uKGOnbHzzJIhiemKxcnnu[{B4cWymIIT5dIUhTUeIUjDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMUKuO\|Eh\|ryP	Mn3RNlM3Pjh2NEG=
NCI-H1975	MUPDfZRwfG:6aXOgRZN{[Xl?	NWHSTW86OTBizszN	MVO3NkBp	MXfEUXNQ	NW[3PFA5S3m2b4TvfIlkcXS7IHHnZYlve3RiZ3XmbZRqdmmkLYLld4l{fGGwdDDoeY1idiCQQ1mtTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEe5NG0h\G:3YnzlJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiNj65NVch\|ryP	NIn6UHIzOzZ4OES0NS=>
16HBE	NYfieIp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWLBXpN4PzJiaB?=	Mn;GSG1UVw>?	NEHBcWVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIEG2TGJGKGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEWJRmKge4l1cCCLQ{WwJI9nKDFwNkCxJO69VQ>?	NVrzNZhIOjN5OUKzNVg>
16HBE	M2LvdmZ2dmO2aX;uJGF{e2G7	NU\W[ZFKOTByIN88US=>	MkjSNVUxKG2rbh?=	MV7EUXNQ	MoWzTY5lfWO2aX;uJI9nKG6rdILpZ{BwgGmmZTDwdo9lfWO2aX;uJIlvKGi3bXHuJFE3UEKHIHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXHSnI>	NIXmWXUzOzd7MkOxPC=>
A549	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVHEVnJlPzJiaB?=	MoW5SG1UVw>?	MmH0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDD3bYxlKHS7cHWgSWdHWi:tLWLhd{Bl\XCnbnTlcpQhcHWvYX6gRVU1QSClZXzsd{B4cXSqIFnDOVAhd2ZiND62NlYh\|ryP	M2PoUVI{Pzl{M{G4
SH-SY5Y	NEi1VXpEgXSxdH;4bYMhSXO\|YYm=		NXXwRlV{PzJiaB?=		MYnJR\|UxRTF6LkKxJO69VQ>?	M1faclI{QDdzOUC5
LoVo	NVn6VnpQU2mwYYPlJGF{e2G7		NVOyPYt3OiBiaB?=	M{nHOWROW09?	MXrJcohq[mm2aX;uJI9nKEWJRmKgdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjB4MjFOwG0>	NFraXnMzOzl\|MEm5OC=>
PC9	M{XVcmtqdmG\|ZTDBd5NigQ>?		NXfySlJROiCq	MXvEUXNQ	M{mzTWlvcGmkaYTpc44hd2ZiRVfGVkBmgG:wIEG5JIRmdGW2aX;uJIFkfGm4YYTpcochdXW2YX70JJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDQR\|kh[2WubIOge4l1cCCLQ{WwJI9nKDBwMEC4O{DPxE1?	NGG3VGIzOzl\|MEm5OC=>
HCC827	NVH2cZY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NED6OYs4OiCq		M2nrXWlEPTB;MD6wNVIh\|ryP	MUOyN\|k4OzF4OB?=
A549	MWDLbY5ie2ViQYPzZZk>	M1XiPFEh\|ryP	Ml3ONUBp	NGXBXIlFVVOR	MUDJcohq[mm2aX;uJI9nKEWJRmKgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wN\|k6KM7:TR?=	Mn3HNlM6QDh\|NUS=
A549	NY\DcHRXTnWwY4Tpc44hSXO\|YYm=	M3y1T\|Eh\|ryP	NHG1eZcyKGh?	NV3MeZNSTE2VTx?=	M{jhR2NmdGy3bHHyJJVxfGGtZR?=	MnjVNlM6QDh\|NUS=
HCC827	NWTOR4ZXU2mwYYPlJGF{e2G7	MXqwMlUh\|ryP	M4HPWlIhcA>?	Mlf4SG1UVw>?	NEnSV4NKdmirYnn0bY9vKG:oIFXHSnIheGixc4Doc5J6dGG2aX;uJIlvKGenZnn0bY5q[i2{ZYPpd5RidnRiaIXtZY4hUEOFOEK3JINmdGy\|	NX3s[21qOjN7OUOzNlg>
HCC827	MnqwSpVv[3Srb36gRZN{[Xl?	NFn5bpcxNjVizszN	NGDKNG4zKGh?	NVrKVGJrTE2VTx?=	NV3CS3NPUW6qaXLpeIlwdiCxZjDjMW1mfCCyaH;zdIhwenmuYYTpc44hcW5iZ3XmbZRqdmmkLYLld4l{fGGwdDDoeY1idiCKQ1O4Nlch[2WubIO=	MlzQNlM6QTN\|Mki=
HCC827	M{fnWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXWxNEDPxE1?	M2TJfFczKGh?	MXjEUXNQ	Mnv4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDn[YZqfGmwaXKtd4Vve2m2aY\lJIh2dWGwIFjDR\|gzPyClZXzsd{Bp[XKkb4LpcochTUeIUjDFO\|Q3KHSxIFG3OVAh\GWuZYTpc44hf2m2aDDJR\|UxKG:oIECuNFA2QDFizszN	Mo\tNlQxPTN4N{S=
A431	NHO2PFFMcW6jc3WgRZN{[Xl?	MlPPNVAxKM7:TR?=	NUmzOHF{OzBibXnu		NVvlcJNFUW6qaXLpeIlwdiCxZjDFS2ZTKGmwIIPo[YQhdWWvYoLhcoUhfmW\|aXPs[ZMhf2m2aDDJR\|UxKG:oIEGuNUDPxE1?	Mk\mNlQxQTR2M{K=
BCRP-MDCK2	NWDtb4htTnWwY4Tpc44hSXO\|YYm=	NILmcY0yNjhizszN	M4[0bVczKGh?	NFPMVm1FVVOR	M3rKSGlv[3KnYYPlJI9nKHCuYYPtZUBu\W2kcnHu[UBmgHC{ZYPzbY9vKG:oIFLDVnAh\XiycnXzd4lv\yC{ZYDvdpRmeiCpZX7lJGdHWA>?	NXHvfG14OjRzOESyNVM>
BCRP-MDCK2	MXXGeY5kfGmxbjDBd5NigQ>?	NHTCNYQyNjhizszN	MWi3NkBp	Mn[ySG1UVw>?	MkCwVoVlfWO2aX;uJI9nKHCuYYPtZUBu\W2kcnHu[UBmgHC{ZYPzbY9vKG:oIFLDVnAh\XiycnXzd4lv\yC{ZYDvdpRmeiCpZX7lJGdHWA>?	Mnu4NlQyQDR{MUO=
MDCK	NUOzWZJmS3m2b4TvfIlkKEG\|c3H5		MV63NkBp	MlHLSG1UVw>?	NHPxd\|FIUTVyPUGuOFUh\|ryP	MWiyOFE5PDJzMx?=
MDCK2	NVLKV5hTTnWwY4Tpc44hSXO\|YYm=	NHLiNW0yNjhizszN	MnT2O\|IhcA>?	M2GwfGROW09?	NEjXdWJKdmirYnn0bY9vKG:oIHj1cYFvKEKFUmCg[ZhxemW\|c3XkJIF{e2W\|c3XkJIF{KEixZXPod5QhOzN\|NEKgZYNkfW23bHH0bY9vKHerdHigTWM2OCCxZjCzMlE6KM7:TR?=	MlTtNlQyQDR{MUO=
A431	NF\0[2lEgXSxdH;4bYMhSXO\|YYm=		NXu4e41qPzJiaB?=	M3zVTWROW09?	MU\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJIV5eHKnc4PpcochTUeIUjD3bZRpKEmFNUCgc4YhOC53NTFOwG0>	MYSyOFQyOTF{Mx?=
Calu3	Mm\kR5l1d3SxeHnjJGF{e2G7		MUm3NkBp	MUDEUXNQ	MkfpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR4FtfTNiY3XscJMh\XiycnXzd4lv\yCKRWKyJJdqfGhiSVO1NEBw\iByLkm5JO69VQ>?	M{Ptb\|I1PDFzMUKz
KB	MnfoT4lv[XOnIFHzd4F6	MYqxNEDPxE1?	M1zueFEhcA>?	Mkj6SG1UVw>?	NH7jRnZKdmirYnn0bY9vKG:oIFXHSk1{fGmvdXzheIVlKGG3dH;wbI9{eGixconsZZRqd25ib3[gSWdHWiC5aYToJGlEPTBib3[gNE4xOjVizszN	M1znNlI1PDFzMUKz
BEAS2B	NYTNTmdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGm1Roc2OCEQvF2=	M3PIbVczKGh?	M2DrNmROW09?	NVr0fWE3UUN3ME2xN{46PCEQvF2=	M3XENFI1PjB5NUmx
NCI-H1975	NHjVcXlHfW6ldHnvckBCe3OjeR?=	NH23R3IyODBizszN	M1v6ZVE2OCCvaX6=	MWnEUXNQ	NHH5NJhKdmS3Y4Tpc44hd2ZiTl:gdJJw\HWldHnvckBqdiCqdX3hckBPS0lvSEG5O\|Uh[2WubIOgbIFz[m:{aX7nJGVITlJiTEi1PHIwXDd7MF2gcZV1[W62	M1ThRVI1PjB5NUmx
Hela	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF;QbJUzPCCq	Ml;3SG1UVw>?	M3fDRWlEPTB;Mj62O{DPxE1?	MV[yOFc{OTJ6MR?=
HepG2	NYT0bYJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWTPNldjOjRiaB?=	NW\aRVBvTE2VTx?=	MVfJR\|UxRTZwNEKg{txO	MUCyOFc{OTJ6MR?=
Sf9	NIT1cHJMcW6jc3WgRZN{[Xl?		Mn[wNVAhdWmw	NHvzNm1FVVOR	MkfKTY5pcWKrdHnvckBw\iCjdYTvdIhwe3Cqb4L5cIF1cW:wIH;mJJJm[2:vYnnuZY51KGircz30ZYdo\WRiRVfGVkAp[W2rbn:gZYNq\CB4NEWtNVE5PiliZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAxNjB{IN88US=>	M2\YdFI1PzNzMkix
SW620	MV\DfZRwfG:6aXOgRZN{[Xl?		NXTa[mF3PDhiaB?=	NFn0XJZFVVOR	Mme4TWM2OD1{OD6yJO69VQ>?	Mm\hNlQ6ODB3OUS=
HCC827	M4eze2Z2dmO2aX;uJGF{e2G7	M{XFUFAvPSEQvF2=	NVXhPHJsOiCq	M1KyTGROW09?	NHu3bopld2W\|IH7veEBqdmirYnn0JIMuVWW2IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiQVvUJJBpd3OyaH;yfYxifGmxbh?=	M4PFSVI{QTl\|M{K4
HCC827	NF;QTpNHfW6ldHnvckBCe3OjeR?=	NY\EVXBqOC53IN88US=>	MoTONkBp	NHjTXJFFVVOR	MX7kc4V{KG6xdDDpcohq[mm2IHOtUYV1KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YheDR2L{SyJJBpd3OyaH;yfYxifGmxbh?=	M1zuSFI{QTl\|M{K4
HCC827	NV\1[JRpS3m2b4TvfIlkKEG\|c3H5	M2j0flAvPSEQvF2=	MmnMO\|IhcA>?	NI\BNlFFVVOR	NXLpU2s3cGG\|IH7vJIN6fG:2b4jpZ4l1gQ>?	NFX4[5MzOzl7M{OyPC=>
NCI-H1975	MUjGeY5kfGmxbjDBd5NigQ>?	NF73[2QyOCEQvF2=	MYG4JIg>	Mmq3SG1UVw>?	MYPkc4V{KG6xdDDpcohq[mm2aTDFS2ZTKGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBGWkticHjvd5Bpd3K7bHH0bY9v	NXe0R4NZOjNzMU[xOlg>
A431	MmTCT4lv[XOnIFHzd4F6	MUKxJO69VQ>?	M2PxT\|EhcA>?	NITDO\|lFVVOR	NF:5d3Rp[XNibn:gbZJz\X[ncoPpZoxmKGmwaHnibZRqd25ib3[gSWdHWiCjdYTvdIhwe3Cqb4L5cIF1cW:w	M{POelI1QTByNUm0
LNCaP	M13iOGZ2dmO2aX;uJGF{e2G7	NUPkTFNrOTBizszN	MmfKNoghd3JiNDDo	M17FemROW09?	NHHhTm1ld2W\|IH7veEBqdmirYnn0JIF2fG:yaH;zdIhwenmuYYTpc44hd2ZiaX3teY5weHW{aX\p[YQh\myjZz30ZYdo\WRiQn34JIF{e2W\|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzN{UG3BWHA>	NHXhVoMyQDZ4N{OxNi=>
H1975	NV3seZp2U2mwYYPlJGF{e2G7	MkL4NUDPxE1?	MUWyOEBp	NFjCc21FVVOR	MVrkc4V{KG6xdDDpcohq[mm2IFXHSnIheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGgyQTd3IHPlcIx{KGijcnLvdolv\yCHR1\SJGw5PTiUL2S3PVBOKG23dHHueC=>	M1r5V\|I1PjB5NUmx
H1975	MXnGeY5kfGmxbjDBd5NigQ>?	NXfScVA6OSEQvF2=	NIXZfIEzPCCq	NWjkcIZETE2VTx?=	NYrvVI9b\G:nczDuc5QhcW6qaXLpeEBGWkticHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEhzOUe1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSM3Q4QTCP	M2j2TVI1PjB5NUmx
HCC827	M3fZ[WtqdmG\|ZTDBd5NigQ>?	NWfFUHdsOC5zMTFOwG0>	MYexJIg>	NULpZo5DTE2VTx?=	NYTo[np7cGG\|IH7vJIlzemW4ZYLzbYJt\SCrbnjpZol1cW:wIH;mJGVITlJiYYPz[ZN{\WRiYYOgdoVkd3[ncomgc4YhTUeIUjDheZRweGixc4Doc5J6dGG2aX;u	NEi3ZVkzPDF{NEi5PC=>
H1975	M1XC[2tqdmG\|ZTDBd5NigQ>?	NV61cZl5OC5\|MzFOwG0>	NETIVFkzKGh?	NVziR4lJTE2VTx?=	MlnB[I9meyCwb4SgbY5pcWKrdDDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGFMXCCyaH;zdIhwenmuYYTpc44>	NIfoV5AzPDF{NEi5PC=>
H1975	NGLUTpJMcW6jc3WgRZN{[Xl?	NIXMPGExNjN\|IN88US=>	NULx[lhVOiCq	M1nsU2ROW09?	M3\vcoRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBGWkticHjvd5Bpd3K7bHH0bY9v	M1;xXVI1OTJ2OEm4
H1975	NHzXRppMcW6jc3WgRZN{[Xl?	MVKwMlM{KM7:TR?=	MYOyJIg>	Moj1SG1UVw>?	NUPjWpRj\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnRicHjvd5Bpd3K7bHH0bY9v	NITOVJUzPDF{NEi5PC=>
H1975	MX\LbY5ie2ViQYPzZZk>	Mo\LNE4yOjVizszN	MVmyOEBp	MWjEUXNQ	NETncHJld2W\|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2gcZV1[W62IGmxNFY5KGG3dH;wbI9{eGixconsZZRqd25?	NFmzZpIzOjN\|OUO0Ni=>
H1975	MnfmT4lv[XOnIFHzd4F6	NXLGdXVxOC53IN88US=>	MXyyOEBp	M3f5TWROW09?	NEHJWYxld2W\|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2gcZV1[W62LX3l[IlifGWmIFXyb{BxcG:\|cHjvdplt[XSrb36=	NHnhWmgzOjN\|OUO0Ni=>
H1975	M3;XdWtqdmG\|ZTDBd5NigQ>?	MWWwMlUh\|ryP	NVPVZnpYOjRiaB?=	MVTEUXNQ	NGLOS5Jld2W\|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2gcZV1[W62LX3l[IlifGWmIFHreEBxcG:\|cHjvdplt[XSrb36=	M{exR\|IzOzN7M{Sy
MIAPaCa2	M3HYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\RNk42KM7:TR?=	M2PiTVczKGh?	NGPpUWxFVVOR	NV62PWRicGG\|IH7vJIdzd3e2aDDpcohq[mm2aX;u	NGD4eG0zODR4NkW1OS=>
MIAPaCa2	NUf2boR5S3m2b4TvfIlkKEG\|c3H5	NF;2XXcyKM7:TR?=	MWixNEBl	MnnESG1UVw>?	MXLoZZMhdm9iY4n0c5RwgGmlaYT5JIF{e2W\|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJINwdG:weTDmc5Ju[XSrb36=	MXqyNFQ3PjV3NR?=
MIAPaCa2	MmW1RZBweHSxc3nzJGF{e2G7	NF\NWHcyOCEQvF2=	NHjjb4UzPGhib4KgOFghcA>?	NF\ZWYNFVVOR	NFHQS4xld2W\|IH7veEBqdmS3Y3WgZZBweHSxc3nz	MYCyNFQ3PjV3NR?=
MIAPaCa2	Mo\jRZBweHSxc3nzJGF{e2G7	M{HQV\|IxKM7:TR?=	MYeyOEBp	MUfEUXNQ	M3qzSoRw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYOgZZN{\XO\|ZXSgZZMh[2G\|cHHz[UA{KGGldHn2ZZRqd25?	NXeyT5VNOjB2Nk[1OVU>
EoL-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTVwMUegcm0>	MWLTRW5ITVJ?
NCI-H720	NFTmS4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;PTWlEPTB;Mk[uPVIhdk1?	NV3KVFVMW0GQR1XS
NCI-SNU-5	NGTR[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHrO\|JKSzVyPUK4MlE6KG6P	MU\TRW5ITVJ?
EW-3	MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TTTGlEPTB;NE[uNFQhdk1?	NVS1cnZrW0GQR1XS
HCC2218	NVeyNXBoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HMNGlEPTB;NUCuOVkhdk1?	MWXTRW5ITVJ?
HuO-3N1	NX\5e41qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTV4LkC5JI5O	Mlj3V2FPT0WU
DB	NI[2Wm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{ewVGlEPTB;NkCuPVYhdk1?	MY\TRW5ITVJ?
HSC-4	M4TvXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWS4OJU{UUN3ME22NU42OyCwTR?=	NXuyO4t[W0GQR1XS
DOK	NVi3WXhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PvV2lEPTB;OUOuOlIhdk1?	M3f1XHNCVkeHUh?=
H9	NHHpTIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTF\|Nz6yJI5O	NUX3XHJIW0GQR1XS
NCI-H292	MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvDUWRmUUN3ME2xOlIvPjZibl2=	Mo\3V2FPT0WU
HSC-2	MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fXW2lEPTB;MU[1MlU4KG6P	NED2Vm9USU6JRWK=
LU-65	NVHHdmV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXKdIFKSzVyPUG2Ok43OSCwTR?=	M{LZcXNCVkeHUh?=
BV-173	M3jRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTLTWM2OD1zOE[uOVUhdk1?	NFHGV5lUSU6JRWK=
LB2241-RCC	NEe5NopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzU[IFKSzVyPUG5OE46OyCwTR?=	NVnB[GpxW0GQR1XS
KG-1	MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;RUIxKSzVyPUKwOE4{PCCwTR?=	MUnTRW5ITVJ?
CHL-1	NFjU[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTMSmZKSzVyPUKwPE42OSCwTR?=	MWnTRW5ITVJ?
KYSE-140	M1;nNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DvWGlEPTB;MkC5Mlk3KG6P	M1jjVXNCVkeHUh?=
DU-145	NUnLZ3czT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHNbHpKSzVyPUKxPU4xPCCwTR?=	MlPQV2FPT0WU
EW-13	NIPTO3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\tcGNKSzVyPUKyOU4yKG6P	M1jQVHNCVkeHUh?=
KYSE-450	M1q4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWe4blRLUUN3ME2yOFcvQTJibl2=	NH6xSldUSU6JRWK=
CAL-72	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjQfZBWUUN3ME2yOlgvPzNibl2=	MWHTRW5ITVJ?
MEG-01	M1PiUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3r1XWlEPTB;Mke2Mlc3KG6P	MoWwV2FPT0WU
HCE-T	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrm[GJKSzVyPUK3PU44QSCwTR?=	MY\TRW5ITVJ?
NCI-SNU-1	M3L2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTJ6Mz6zNkBvVQ>?	NV;PcncyW0GQR1XS
CAL-27	NF:1Z2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHKfpdlUUN3ME2yPFkvODhibl2=	MlW1V2FPT0WU
BALL-1	M2TmXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XZV2lEPTB;Mkm3MlQzKG6P	NV;v[JNyW0GQR1XS
SBC-1	NH[3boZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHqTWM2OD1\|MEeuO\|khdk1?	MmTjV2FPT0WU
CAL-54	NIXGbYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnJZYlpUUN3ME2zNVEvOjNibl2=	MYDTRW5ITVJ?
TI-73	M2T2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTNzMj63OUBvVQ>?	MkfIV2FPT0WU
P12-ICHIKAWA	NUiw[YxVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4q1[mlEPTB;M{K4MlA3KG6P	NG\sOJdUSU6JRWK=
ACHN	NXvQPYtJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFv3WXdKSzVyPUOzNU41KG6P	M3XDbnNCVkeHUh?=
PC-14	NF;tSHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfXdIRKSzVyPUOzN{41OSCwTR?=	NWXjOGtkW0GQR1XS
HCC1806	M1fUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIna[llKSzVyPUOzO{42OSCwTR?=	NEiyNpRUSU6JRWK=
SK-MEL-24	NVnOfpV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjVZWdKSzVyPUOzO{45PyCwTR?=	MV;TRW5ITVJ?
A4-Fuk	NInvVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzE[2tEUUN3ME2zOVAvODJibl2=	NU\MSJFGW0GQR1XS
ECC10	NGiwbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjnZplKSzVyPUO1Nk46PiCwTR?=	NG\6TWlUSU6JRWK=
KASUMI-1	MoDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTHUmxIUUN3ME2zOlYvPzNibl2=	NIXQXnlUSU6JRWK=
CAL-33	NXrNd\|lGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3X1cGlEPTB;M{ewMlkhdk1?	Mo\3V2FPT0WU
MDA-MB-175-VII	MnjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrkTWM2OD1\|N{iuPFghdk1?	M3HXd3NCVkeHUh?=
NUGC-3	NX;CfI5{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHkSmZKSzVyPUSwNU45OSCwTR?=	Mmq0V2FPT0WU
KY821	NGj5VFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTRyOD61O{BvVQ>?	MX7TRW5ITVJ?
CTB-1	MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTR{ND60JI5O	M4OybXNCVkeHUh?=
DoTc2-4510	NE[zS49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTR2Mj6xNkBvVQ>?	MmXBV2FPT0WU
EFO-27	MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PHUGlEPTB;NEW0Mlc1KG6P	MVzTRW5ITVJ?
BPH-1	Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILT[HVKSzVyPUS5NU4yPiCwTR?=	MWPTRW5ITVJ?
KYSE-270	M{Xoc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPRZ\|NKSzVyPUS5PE43PSCwTR?=	MlrJV2FPT0WU
HO-1-N-1	NImy[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTVyOT6yOUBvVQ>?	NHXUfmlUSU6JRWK=
SK-MEL-1	M4SyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHNTWM2OD13MUCuPVkhdk1?	MnTJV2FPT0WU
MOLT-13	M4Xsb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7YTWM2OD13MUSuPFIhdk1?	M3LvNHNCVkeHUh?=
TK10	MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTVzNT6xNUBvVQ>?	NXva[\|NWW0GQR1XS
HN	M3v3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXDTWM2OD13MUeuN\|ghdk1?	NXrVOXY5W0GQR1XS
SCC-15	NXX1[YNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\FTWM2OD13MkWuOlghdk1?	NYiwNlFlW0GQR1XS
NCI-H358	M{j5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHEW2MxUUN3ME21NlcvPjZibl2=	MkfuV2FPT0WU
KYSE-180	NHnoSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTV\|MD62NkBvVQ>?	MXvTRW5ITVJ?
NCI-H82	MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTV2MD61JI5O	NYnFRpVtW0GQR1XS
NB7	NFizc5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4nBSmlEPTB;NUS2MlMzKG6P	Mk\6V2FPT0WU
DSH1	M4PKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mme0TWM2OD13Nk[uPFghdk1?	NGjNXlFUSU6JRWK=
RS4-11	M3nYXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfRTWM2OD13NkiuOVkhdk1?	M4GySHNCVkeHUh?=
CAN	M2Xu[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTV6MD63OkBvVQ>?	M3G4cHNCVkeHUh?=
Ca9-22	MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLyUoZvUUN3ME21PFgvPjRibl2=	M{DEfHNCVkeHUh?=
CAL-39	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWG1WWJbUUN3ME21PVYvOyCwTR?=	M{nlUXNCVkeHUh?=
NCI-H1623	NGnje5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTV7OT6zOkBvVQ>?	MkCzV2FPT0WU
FADU	M4TWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTyfoJKSzVyPU[wOE43QSCwTR?=	MW\TRW5ITVJ?
NB69	NF;wbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX76OnJyUUN3ME22NVQvOzVibl2=	MnXTV2FPT0WU
Ramos-2G6-4C10	M2PreGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTZ{MT60OkBvVQ>?	M3;UNnNCVkeHUh?=
LB1047-RCC	M{K5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DNVGlEPTB;NkK1MlI6KG6P	NH\odIxUSU6JRWK=
MV-4-11	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnVeVkyUUN3ME22NlcvPyCwTR?=	MlTwV2FPT0WU
DBTRG-05MG	M1f0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTZ\|Mj6yPEBvVQ>?	M1HiRXNCVkeHUh?=
ME-180	MlPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETi[JNKSzVyPU[zNk46KG6P	NIqzTW9USU6JRWK=
NBsusSR	NIXFfHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTZ2Nj61NkBvVQ>?	NYrmUFRWW0GQR1XS
COR-L105	NVjxZVJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\xeFQ4UUN3ME22OlIvPTNibl2=	MmPsV2FPT0WU
ETK-1	MnPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjmdFBSUUN3ME22OlIvPTlibl2=	NYfiXlljW0GQR1XS
L-363	MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF71T29KSzVyPU[3NU46PCCwTR?=	M2jLSHNCVkeHUh?=
LU-134-A	M2nS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXlXGlKSzVyPUexPU4xQSCwTR?=	NFKyfWFUSU6JRWK=
NCI-H1770	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHe3dnpKSzVyPUeyNk41KG6P	MnzHV2FPT0WU
HAL-01	NVThbJZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvpTWM2OD15M{SuO\|Ehdk1?	MVfTRW5ITVJ?
COLO-684	NGfaZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnCTWM2OD15NUOuNFEhdk1?	Mlj6V2FPT0WU
TE-6	NIXXbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\jbGlEPTB;N{[0MlMyKG6P	M2fuU3NCVkeHUh?=
A431	M4\6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXJc3ZKSzVyPUe4NE4xPCCwTR?=	NUHZUpdsW0GQR1XS
LU-135	NX7uRXVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjIO3p2UUN3ME23PFMvODNibl2=	MlX3V2FPT0WU
EC-GI-10	NXnuO29NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTd6OD61NkBvVQ>?	MWfTRW5ITVJ?
TE-12	NFmxXFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDWXnp{UUN3ME24NlEvOTFibl2=	NWT1cnZtW0GQR1XS
LoVo	MnzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrRdW5ZUUN3ME24OVkvODZibl2=	MnLkV2FPT0WU
23132-87	M4XSU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjBdGlDUUN3ME24OlQvOjhibl2=	NEjzZ3FUSU6JRWK=
AU565	NVTNSFF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3jTWM2OD16NkmuOkBvVQ>?	MXnTRW5ITVJ?
DEL	NV63TFNPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1q0[WlEPTB;OEe3MlY2KG6P	Ml[yV2FPT0WU
COR-L88	NXz0NXF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XJSWlEPTB;OEiyMlI3KG6P	Mn7SV2FPT0WU
NCI-H2126	MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PYb2lEPTB;OEiyMlg{KG6P	NYT3PGZDW0GQR1XS
CAPAN-1	MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHLTWM2OD16OEOuNlkhdk1?	MVPTRW5ITVJ?
BT-474	Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1y3PGlEPTB;OUO4MlE1KG6P	NHLP[nNUSU6JRWK=
BHY	NFzxSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zye2lEPTB;OUe1MlQ5KG6P	NFHxeG9USU6JRWK=
HT-3	NVTJeG85T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTl6Mj60NUBvVQ>?	MnXDV2FPT0WU
SK-NEP-1	NYHjSHZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPkfGxyUUN3ME25PFkvPDRibl2=	NYfSNVVbW0GQR1XS
MS-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LXSWlEPTB;OUm0MlY6KG6P	NUW4XmkzW0GQR1XS
DOHH-2	MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXxNGtsUUN3ME2xMlAxODJzIN88US=>	NX;EcYNQW0GQR1XS
NCI-H1304	NIPTWWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDiTWM2OD1zLkCxOlQ{KM7:TR?=	Mn7CV2FPT0WU
EM-2	NXy4[WFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXX5XWgyUUN3ME2xMlA{ODF4IN88US=>	Mor0V2FPT0WU
MHH-PREB-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX7YUIxDUUN3ME2xMlA5PDVzIN88US=>	MnjEV2FPT0WU
KU-19-19	M1nSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fIfGlEPTB;MT6wPFU1OSEQvF2=	NXPzVmlLW0GQR1XS
NCI-H1648	MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXCTWM2OD1zLkGwOlE3KM7:TR?=	M2e5RnNCVkeHUh?=
MKN1	NX\xSm9IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXCclNDUUN3ME2xMlIyQTh5IN88US=>	NUi5SVg4W0GQR1XS
SNU-449	Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nvWmlEPTB;MT6yNlIxQCEQvF2=	NXm1THFpW0GQR1XS
OAW-42	MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfONFc5UUN3ME2xMlI4QDJ3IN88US=>	MmWwV2FPT0WU
769-P	MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7lTXpKSzVyPUGuNlc6OThizszN	MX\TRW5ITVJ?
SW1088	M13YbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4G0NGlEPTB;MT6yPVYxPyEQvF2=	M2DsfHNCVkeHUh?=
GCIY	NYS1XGlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jBdWlEPTB;MT6zNFE{OiEQvF2=	Ml20V2FPT0WU
CTV-1	M{LEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTlTWM2OD1zLkOwPEDPxE1?	M1zOOHNCVkeHUh?=
NCI-H1092	M4DYN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3RTWM2OD1zLkOwPFUh\|ryP	NEHlc5VUSU6JRWK=
NKM-1	M1jLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInNWYtKSzVyPUGuN\|I2QTdizszN	NXrjRlgxW0GQR1XS
NCI-H1650	NGPWUW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;WSGlEPTB;MT6zN\|Q5OiEQvF2=	NFvCeJlUSU6JRWK=
SW954	MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGn0S4FKSzVyPUGuN\|QxPDhizszN	NULlcotxW0GQR1XS
SW48	NVf2U3oxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1P5[WlEPTB;MT6zOlYyQCEQvF2=	M1HVfHNCVkeHUh?=
SK-N-DZ	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\1TWM2OD1zLkO2PVQ4KM7:TR?=	MVnTRW5ITVJ?
KMOE-2	MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjFTWM2OD1zLkO5PFE2KM7:TR?=	M37QVHNCVkeHUh?=
NB5	M2f1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIO1N2VKSzVyPUGuOFA5QTRizszN	MV\TRW5ITVJ?
CCRF-CEM	NHP2N3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LMcmlEPTB;MT60NVEyKM7:TR?=	NVnSUoFyW0GQR1XS
RH-1	NWDRfHRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmX2TWM2OD1zLkSxNVM3KM7:TR?=	NVnBbo9bW0GQR1XS
NCI-H526	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fi[GlEPTB;MT60N\|gzPiEQvF2=	Mon4V2FPT0WU
697	MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DuUGlEPTB;MT60OFExPCEQvF2=	MoL0V2FPT0WU
J82	M3rEXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTFwNEW3OlYh\|ryP	M3HmWHNCVkeHUh?=
BE-13	M{[weWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTvTWM2OD1zLkWwOlcyKM7:TR?=	NXe1NHhTW0GQR1XS
SAS	M3nSNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\lSGlEPTB;MT61NVYzOiEQvF2=	NF\vcZJUSU6JRWK=
SCC-25	MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\nTWM2OD1zLkWyN\|IzKM7:TR?=	NGf6U41USU6JRWK=
LAMA-84	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIL2WZVKSzVyPUGuOVM5OTVizszN	M3PB[XNCVkeHUh?=
HSC-3	M1H6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTFwNUSzPEDPxE1?	NHLZR4pUSU6JRWK=
BT-549	M3q5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHCOZdPUUN3ME2xMlU5PzR5IN88US=>	NEfOOGdUSU6JRWK=
ML-2	M{LO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\NTWM2OD1zLk[0NFI6KM7:TR?=	MkfTV2FPT0WU
BB30-HNC	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTISpo1UUN3ME2xMlY5QTd{IN88US=>	M3HqOXNCVkeHUh?=
PANC-03-27	MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTFwN{CxN\|kh\|ryP	NIrY[5RUSU6JRWK=
COLO-678	M1\DUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2ntRmlEPTB;MT63N\|Q1PCEQvF2=	MmfkV2FPT0WU
NCI-H1666	NH7IUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrBZlJKSzVyPUGuO\|Q4ODRizszN	NEjOTXpUSU6JRWK=
NCI-H209	MmTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYftRXU5UUN3ME2xMlc4OjZ7IN88US=>	M3u3d3NCVkeHUh?=
EPLC-272H	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfxTWM2OD1zLki1OVQ6KM7:TR?=	MV;TRW5ITVJ?
OMC-1	M1TUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHVb3hKSzVyPUGuPVk5QDhizszN	NILWb2pUSU6JRWK=
HCC70	NFnhZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTJwMEC4NVUh\|ryP	MVXTRW5ITVJ?
CAL-12T	NF7P[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLlTWM2OD1{LkCxPFYyKM7:TR?=	MVvTRW5ITVJ?
TGBC24TKB	NIjtXZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHmW3dKSzVyPUKuNFI6PjFizszN	NE\K[Y1USU6JRWK=
EKVX	NGTvdHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LKeWlEPTB;Mj6wOFk{QSEQvF2=	M4\KPHNCVkeHUh?=
SW1116	M{THNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\DTWM2OD1{LkC2NFA6KM7:TR?=	NUHse\|FDW0GQR1XS
NCI-H2009	NFXFcJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTJwME[yNVQh\|ryP	NUX1bJZCW0GQR1XS
RPMI-8866	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfrNpo1UUN3ME2yMlA5PDhzIN88US=>	MWjTRW5ITVJ?
KARPAS-45	NXrZPFBGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPnfpdNUUN3ME2yMlEzPDd7IN88US=>	NF;GWWZUSU6JRWK=
RXF393	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTJwMUOwN\|Yh\|ryP	NHX0[YVUSU6JRWK=
786-0	NV7hbmxHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nHbGlEPTB;Mj6xPFQxPiEQvF2=	M1;Xb3NCVkeHUh?=
SCC-4	Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLhW5pKSzVyPUKuNlE4PzZizszN	M1q4bHNCVkeHUh?=
BT-20	NGq4WIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTJwMk[3OFQh\|ryP	NYrUcmpyW0GQR1XS
A498	NWfVNIY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTJwMkm0NVUh\|ryP	MmTZV2FPT0WU
IGROV-1	M1rBZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\M[\|dTUUN3ME2yMlMyOjN5IN88US=>	NX\HclFOW0GQR1XS
JVM-3	Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTJwM{S2OFMh\|ryP	MmrLV2FPT0WU
NCI-H2170	MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3L3T2lEPTB;Mj6zOFc5OyEQvF2=	MoTWV2FPT0WU
EW-18	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjoTWM2OD1{LkO1OFcyKM7:TR?=	NGriTZpUSU6JRWK=
KU812	NWnCN281T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTTTWM2OD1{LkO2O\|c6KM7:TR?=	M{fDOnNCVkeHUh?=
NY	MlnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTJwM{eyO{DPxE1?	NXLSdFljW0GQR1XS
HTC-C3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTOSldOUUN3ME2yMlQzOjZ5IN88US=>	NIXpRopUSU6JRWK=
CFPAC-1	MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDKdHUyUUN3ME2yMlQ{QDZ2IN88US=>	NIrPZWxUSU6JRWK=
HH	M2XKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TFbmlEPTB;Mj60PVg2PCEQvF2=	NF35NG1USU6JRWK=
MKN7	NYTzTppjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13qOGlEPTB;Mj62Nlc1QCEQvF2=	NULhRYZNW0GQR1XS
TE-8	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTJwNkO2OVMh\|ryP	NFTUboxUSU6JRWK=
MC-IXC	NWHlN4o2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjTb3lKSzVyPUKuOlQ1PTNizszN	MUnTRW5ITVJ?
DMS-79	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTJwNkmyPFQh\|ryP	MULTRW5ITVJ?
Detroit562	Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTJwNkm4OFUh\|ryP	MXnTRW5ITVJ?
HuP-T4	MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTJwN{K4NVgh\|ryP	NXLPXWxCW0GQR1XS
QIMR-WIL	M3GzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFq1[XJKSzVyPUKuO\|U6PTJizszN	MVvTRW5ITVJ?
BB65-RCC	NYrXcJJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnxVIZ[UUN3ME2yMlgxPzF\|IN88US=>	Mm\iV2FPT0WU
PC-3	NF:zRmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHxTWM2OD1{LkizN\|E4KM7:TR?=	NGjldFRUSU6JRWK=
OVCAR-3	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTJwOEW1PVQh\|ryP	NE\VOoVUSU6JRWK=
KYSE-510	NFLKWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXyxO4t{UUN3ME2yMlg3Pzh4IN88US=>	M1S0eXNCVkeHUh?=
HC-1	MmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLibJVKSzVyPUKuPVQxOTJizszN	MnTrV2FPT0WU
NCI-H1693	MnXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XKRWlEPTB;Mj65OVg6PyEQvF2=	MULTRW5ITVJ?
DU-4475	NH\wOI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVG3fINRUUN3ME2yMlk6ODV{IN88US=>	MU\TRW5ITVJ?
COLO-680N	NGjzV5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTNwMEC0PVUh\|ryP	NVzxTIU2W0GQR1XS
MN-60	MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3RTWM2OD1\|LkC0PVc1KM7:TR?=	NF:3NXFUSU6JRWK=
BCPAP	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nW[GlEPTB;Mz6wPFI6PSEQvF2=	MXHTRW5ITVJ?
647-V	MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;nSWlEPTB;Mz6xOlIzKM7:TR?=	MV3TRW5ITVJ?
HT-1376	NUfqSJAyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\DcoVKSzVyPUOuNlA2ODZizszN	NEnPd4dUSU6JRWK=
NCI-H1793	M3LDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jPcmlEPTB;Mz6yNVA6QCEQvF2=	NEfMcHlUSU6JRWK=
SW1463	NWPrcGt6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTNwMk[xPVIh\|ryP	NUDEUWZpW0GQR1XS
NCI-H727	MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTNwM{i1PFQh\|ryP	NID4O3VUSU6JRWK=
LB771-HNC	MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjWTWM2OD1\|LkO5NVI3KM7:TR?=	NYLoPVFrW0GQR1XS
D-542MG	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\zZ5pKSzVyPUOuOFQzOjJizszN	MkH4V2FPT0WU
NTERA-S-cl-D1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU[xUIlVUUN3ME2zMlQ1QTV5IN88US=>	M2DRfXNCVkeHUh?=
C8166	MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTNwNE[1NlEh\|ryP	MlzQV2FPT0WU
639-V	M3fvTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFe5VHBKSzVyPUOuOVc4QTJizszN	M{juZ3NCVkeHUh?=
TE-1	NFXCRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHzTWM2OD1\|LkW5NVY6KM7:TR?=	NHvuVG5USU6JRWK=
OAW-28	M4L4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\xNmlEPTB;Mz61PVQzPiEQvF2=	MmX1V2FPT0WU
SK-LU-1	M3j0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTNwNkC2OFUh\|ryP	MXrTRW5ITVJ?
CaR-1	NYi0SlN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3vTWM2OD1\|Lk[xNFQ5KM7:TR?=	MX3TRW5ITVJ?
A2780	NXnIe2RvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnSVWYyUUN3ME2zMlY1ODh7IN88US=>	MWTTRW5ITVJ?
C2BBe1	NFXDNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkCyTWM2OD1\|Lk[0OFA4KM7:TR?=	MoixV2FPT0WU
SK-MES-1	NX7IPGczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHT2O5RKSzVyPUOuOlQ3OTRizszN	MU\TRW5ITVJ?
PANC-10-05	NYOyV4VLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHOeWNFUUN3ME2zMlczODd{IN88US=>	NVm5fZRWW0GQR1XS
J-RT3-T3-5	M2nm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTNwN{W0NFYh\|ryP	NXTMT4t3W0GQR1XS
ES4	Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFe2U5hKSzVyPUOuPFIzQDZizszN	MWHTRW5ITVJ?
NCI-H28	NGDtXnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTNwOEK5OlEh\|ryP	M2LjWHNCVkeHUh?=
NCI-H1155	M3TnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTNwOESxOVkh\|ryP	NEPYdWRUSU6JRWK=
KURAMOCHI	M3z1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknVTWM2OD1\|Lki2NFU3KM7:TR?=	M3n6S3NCVkeHUh?=
NCI-H69	M{f2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjrbopKSzVyPUOuPVAyPzhizszN	NHW1fVhUSU6JRWK=
IST-MES1	NX\VPZlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTNwOUSwNlkh\|ryP	NEnpbYxUSU6JRWK=
NH-12	M1nkZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInEelFKSzVyPUOuPVQyQDdizszN	NEPtcoJUSU6JRWK=
JVM-2	MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37zVmlEPTB;Mz65OFc2OiEQvF2=	MY\TRW5ITVJ?
EW-16	M3T5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjBUVkyUUN3ME2zMlk2PTd5IN88US=>	NUnVXIdzW0GQR1XS
NCI-H441	MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;tTWM2OD1\|Lkm3NFE1KM7:TR?=	M3zCe3NCVkeHUh?=
RCC10RGB	M{e3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjoO3lKSzVyPUSuNFEzPDZizszN	M4G5UHNCVkeHUh?=
TCCSUP	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLnTWM2OD12LkGxNFUh\|ryP	NGLiXHFUSU6JRWK=
HL-60	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17NR2lEPTB;ND6xNlI1OSEQvF2=	NGjSWmtUSU6JRWK=
EW-11	M3zoN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\wNWdKSzVyPUSuNVMzPjFizszN	NESyNnhUSU6JRWK=
KARPAS-299	NVfRXHhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DwVmlEPTB;ND6zNVAyOyEQvF2=	NWjLOmY6W0GQR1XS
SNU-C2B	M3vyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjVZ\|NKSzVyPUSuN\|Q3QDZizszN	M4jiNHNCVkeHUh?=
LU-139	NUnq[HZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\BTWM2OD12LkO3NlQ4KM7:TR?=	M1\jenNCVkeHUh?=
HCC1937	M3LGV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzMTWM2OD12LkO3PVk{KM7:TR?=	Mn7QV2FPT0WU
GR-ST	M3Tkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWGwRohtUUN3ME20MlQ{OThizszN	NYnYOXFkW0GQR1XS
SK-OV-3	NH3yR4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTRwNE[wOFIh\|ryP	Mo\5V2FPT0WU
A172	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTRwNUW1NlEh\|ryP	M3;tT3NCVkeHUh?=
NB10	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDYUJVnUUN3ME20MlU6PzhzIN88US=>	MmrjV2FPT0WU
P30-OHK	NUC4NWZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4TQXGlEPTB;ND64NVkzQSEQvF2=	NHnre45USU6JRWK=
KYSE-520	NYC0cYF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfwPZRuUUN3ME20Mlg5ODF6IN88US=>	MWTTRW5ITVJ?
KNS-62	MnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTRwOUC4NFch\|ryP	MWXTRW5ITVJ?
ES1	NYjHPXhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLuTWM2OD12Lkm2NFM2KM7:TR?=	MX;TRW5ITVJ?
KOSC-2	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfsOIhKSzVyPUSuPVk6PTlizszN	MmO4V2FPT0WU
TE-9	NGPzNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{K0fWlEPTB;NT6wNVUzPSEQvF2=	MYnTRW5ITVJ?
NCI-H1838	M2LMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTVwMEKwO\|Yh\|ryP	MnrmV2FPT0WU
KP-N-YN	NIXz[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnjNo5KSzVyPUWuNVI2QTFizszN	MnTmV2FPT0WU
ALL-PO	M4nXR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2j1T2lEPTB;NT6yNlU5PyEQvF2=	M3XuVXNCVkeHUh?=
NOMO-1	M2PHcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7oTWM2OD13LkKzNVc3KM7:TR?=	M2\yXHNCVkeHUh?=
CGTH-W-1	NEHNUoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTVwM{i1PFQh\|ryP	MXLTRW5ITVJ?
ATN-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlL3TWM2OD13LkSxNVg1KM7:TR?=	M1;hb3NCVkeHUh?=
AGS	M373fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2G5W2lEPTB;NT60PVYyQCEQvF2=	NHztOoNUSU6JRWK=
SW13	NGjYOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTVwNUOyOlUh\|ryP	M2\IdHNCVkeHUh?=
SW1990	M4eyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUe1fmluUUN3ME21MlYzOjh3IN88US=>	NIH0bllUSU6JRWK=
BFTC-905	MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnuwTWM2OD13Lk[1PFc5KM7:TR?=	NIDMeGFUSU6JRWK=
RMG-I	M1fR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTBdnJbUUN3ME21MlY2QTR{IN88US=>	MkjpV2FPT0WU
HD-MY-Z	MnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2[0bWlEPTB;NT62PFU5OSEQvF2=	Ml3yV2FPT0WU
HCC1187	Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTVwN{GwN\|Ih\|ryP	M{H6bnNCVkeHUh?=
HCC2998	M{nsO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfYWHhpUUN3ME21MlcyQDd5IN88US=>	M{X0XnNCVkeHUh?=
RT-112	MnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTVwOUCyOFUh\|ryP	MnXiV2FPT0WU
CAKI-1	NVjVflVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{Xo[2lEPTB;Nj6wNFk5PSEQvF2=	M3\PfXNCVkeHUh?=
HDLM-2	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jq[mlEPTB;Nj6wNVQ5QSEQvF2=	NHraVpJUSU6JRWK=
TE-10	M3rBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHE[Xl{UUN3ME22MlA1QDN\|IN88US=>	MmXkV2FPT0WU
KE-37	MnO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HMS2lEPTB;Nj6wO\|I2QCEQvF2=	MY\TRW5ITVJ?
RCM-1	NEDEOnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DuWmlEPTB;Nj6wO\|cyQSEQvF2=	MYnTRW5ITVJ?
Mewo	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XkbGlEPTB;Nj6xNVQ5PyEQvF2=	MUfTRW5ITVJ?
L-428	NF3kdVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXuyb21yUUN3ME22MlE5ODN5IN88US=>	NEOwcpBUSU6JRWK=
8-MG-BA	Mm\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jtSmlEPTB;Nj6xPVM4QSEQvF2=	NUHOR3Z2W0GQR1XS
SK-MEL-28	NITFb4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTZwMkC5Olch\|ryP	MXPTRW5ITVJ?
VA-ES-BJ	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUm2bXl7UUN3ME22MlMxPDZ{IN88US=>	NHrMNm9USU6JRWK=
CAL-120	M12zWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXL3fVJFUUN3ME22MlQ2OTZ{IN88US=>	M1ztVXNCVkeHUh?=
GAMG	M{\mPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX33W\|FUUUN3ME22MlUxPjJizszN	MlO5V2FPT0WU
MSTO-221H	M4HDU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7qTWM2OD14LkWxNVch\|ryP	NFrMcFZUSU6JRWK=
GCT	NXnUXVVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIWxfGRKSzVyPU[uOVM{QDdizszN	NXziPJJiW0GQR1XS
SH-4	NXzIb\|RRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vUbWlEPTB;Nj61PFg1PCEQvF2=	NUm5R5RKW0GQR1XS
Calu-3	NHzmcnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2P4WWlEPTB;Nj62OVU3QCEQvF2=	NIfrNWRUSU6JRWK=
SK-HEP-1	NGjORm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPQcYNjUUN3ME22MlcyPzV\|IN88US=>	MYLTRW5ITVJ?
PFSK-1	Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2qxcGlEPTB;Nj63N\|Q4QCEQvF2=	M3LkW3NCVkeHUh?=
NB12	M3;LbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTZwN{i0NFQh\|ryP	NXfa[VJWW0GQR1XS
A388	NXHCWWFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{j6N2lEPTB;Nj64PVUzKM7:TR?=	MWHTRW5ITVJ?
KLE	M330PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTZwOU[1NVYh\|ryP	NIO5c5ZUSU6JRWK=
TE-11	MnrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vRb2lEPTB;Nz6wOFk3PyEQvF2=	M3fHO3NCVkeHUh?=
NCI-H2405	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlT2TWM2OD15LkC4N\|k{KM7:TR?=	NIWye\|VUSU6JRWK=
OVCAR-4	NU\WXVgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\KSWlEPTB;Nz6xOVM2KM7:TR?=	M1\PcnNCVkeHUh?=
KP-N-YS	NFO1cm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvMTWM2OD15LkG4NVQh\|ryP	M3\FNHNCVkeHUh?=
NOS-1	M3KwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M333UmlEPTB;Nz6yOVgzQCEQvF2=	NXixeZRIW0GQR1XS
DMS-114	M4XiOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\qTWM2OD15LkK5OlMyKM7:TR?=	M2fLRnNCVkeHUh?=
NCI-H2030	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTdwM{O2PVgh\|ryP	M{[zcXNCVkeHUh?=
HEL	NHXsO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;0W\|RKSzVyPUeuN\|c2OjFizszN	NYjId49VW0GQR1XS
CAL-62	NHix[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHwTWM2OD15LkO5PFY3KM7:TR?=	MYTTRW5ITVJ?
COLO-668	MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYGxe\|RJUUN3ME23MlQ{QTZ5IN88US=>	MWHTRW5ITVJ?
SKG-IIIa	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4SwfGlEPTB;Nz60OVM5OSEQvF2=	NFzjRlNUSU6JRWK=
HCC1419	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLocVRLUUN3ME23MlQ3QDN\|IN88US=>	NGjFNllUSU6JRWK=
OS-RC-2	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTdwNEm4PVQh\|ryP	MmHKV2FPT0WU
COLO-829	NVjvV\|NqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnPc4tKSzVyPUeuOlY1PjNizszN	NITySoZUSU6JRWK=
NB13	M1zSTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjJcIlKSzVyPUeuPFI3PjdizszN	NEfiRYlUSU6JRWK=
DK-MG	NF3NUJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfQTWM2OD15LkizNlAyKM7:TR?=	MVzTRW5ITVJ?
SHP-77	NHX1dHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTzTWM2OD15Lki2OlU{KM7:TR?=	NXHKNHRQW0GQR1XS
NCI-H661	M2Xuc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3yxPWlEPTB;OD6wOVg3PyEQvF2=	NWjqcGNwW0GQR1XS
AM-38	MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnyTWM2OD16LkG2Nlgh\|ryP	MU\TRW5ITVJ?
VM-CUB-1	NVnF[IdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljJTWM2OD16LkG3NFI6KM7:TR?=	MlvRV2FPT0WU
KYSE-70	NHzMTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\PXphKSzVyPUiuNVk4PjFizszN	NVnCfmVuW0GQR1XS
5637	NYKxUoZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3YUWVKSzVyPUiuN\|ExPTVizszN	Mni2V2FPT0WU
TGBC11TKB	NH3QcXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInSZmFKSzVyPUiuOFYyPjRizszN	NFTSNJFUSU6JRWK=
EGI-1	NVfCPYJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml[4TWM2OD16Lk[wNFg5KM7:TR?=	M3zt[XNCVkeHUh?=
D-392MG	NW\rbXp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnz2TWM2OD16Lk[2NlE1KM7:TR?=	NH3rUFhUSU6JRWK=
A673	M3jPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXOTWM2OD16Lk[3OlEyKM7:TR?=	MnzZV2FPT0WU
COLO-792	Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\KTZhKSzVyPUiuO\|Q6PDZizszN	Mo[2V2FPT0WU
NCI-H1792	Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\ZTWM2OD16Lki4PVA{KM7:TR?=	MmHjV2FPT0WU
LS-1034	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXHTWM2OD16Lkm0OlUzKM7:TR?=	Mn\GV2FPT0WU
D-566MG	NUKweYNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTlwMEG4NUDPxE1?	M2HtT3NCVkeHUh?=
NCI-H226	NUnlNFJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjSTWM2OD17LkC5JO69VQ>?	NEX0U5FUSU6JRWK=
ChaGo-K-1	NVHrV405T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TkUmlEPTB;OT6xNFU4QSEQvF2=	MVXTRW5ITVJ?
NCI-H2228	MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jSOWlEPTB;OT6xNVA5OSEQvF2=	NHPUVmFUSU6JRWK=
RPMI-8226	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7PTWM2OD17LkGxN\|A1KM7:TR?=	NEeyN2hUSU6JRWK=
BFTC-909	NYDmfphrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7TSIhCUUN3ME25MlE5Ojl5IN88US=>	NWe5NZZZW0GQR1XS
HPAF-II	NYLo[5BHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFX6OWNKSzVyPUmuNlI2OThizszN	NIHYbWlUSU6JRWK=
Capan-2	NF[ydFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTlwNECxNFkh\|ryP	MnL4V2FPT0WU
IA-LM	NWDkd21QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPETWM2OD17LkSxPVY3KM7:TR?=	M{XLXnNCVkeHUh?=
KP-4	NFH5T5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHCTWM2OD17LkS4PFM5KM7:TR?=	NXnRT5piW0GQR1XS
A101D	NFLVdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTiTWM2OD17LkWxO\|E6KM7:TR?=	M2TNbnNCVkeHUh?=
EFO-21	M3fNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{i1d2lEPTB;OT61PFc{PSEQvF2=	NEDEOJpUSU6JRWK=
C32	NWDze415T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfzcot4UUN3ME25MlY{OzRizszN	MY\TRW5ITVJ?
SW837	NUH0R4RFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTlwOES4NkDPxE1?	NYDEOHRbW0GQR1XS
OCI-AML2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nTeWlEPTB;OT64Olk3KM7:TR?=	NXK4cYtDW0GQR1XS
NCI-H1355	M{P6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPK[45KSzVyPUmuPVQxQDhizszN	M{W5fHNCVkeHUh?=
NCI-H2342	M2nXfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPUTWM2OD1zMD6wNVU2KM7:TR?=	Mn;SV2FPT0WU
A204	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFv3[HFKSzVyPUGwMlA1PjZizszN	NWjnVFZVW0GQR1XS
CAL-51	NHPyW4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTFyLkC4O\|ch\|ryP	NXn2PYRZW0GQR1XS
HCE-4	NIL0fWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjjenBKSzVyPUGwMlEyOjJizszN	M{HhOXNCVkeHUh?=
NCI-H810	MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGT0Um5KSzVyPUGwMlE2QTdizszN	M17POHNCVkeHUh?=
DJM-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPKTWM2OD1zMD6xO\|MzKM7:TR?=	NEj0fnZUSU6JRWK=
SK-UT-1	NIPLPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7Dd41KSzVyPUGwMlI2PzRizszN	MkLmV2FPT0WU
U031	MlnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HRT2lEPTB;MUCuNlY5PiEQvF2=	NITmOXZUSU6JRWK=
YH-13	NX\4UmhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTFyLkOwOVch\|ryP	Mm\tV2FPT0WU
K5	NEOyb3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DyTmlEPTB;MUCuN\|M6PSEQvF2=	NXiyUlFzW0GQR1XS
HEC-1	M3vYN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHD[HlnUUN3ME2xNE41ODhzIN88US=>	M4jBZnNCVkeHUh?=
A2058	NV\DTXIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTFyLkW0PVEh\|ryP	NX;VbpFOW0GQR1XS
SW962	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfLRZdtUUN3ME2xNE43OjB2IN88US=>	M{TNOXNCVkeHUh?=
VMRC-RCZ	M1vOdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTFyLk[3OFkh\|ryP	MVrTRW5ITVJ?
D-336MG	M2X6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fi[mlEPTB;MUCuO\|AxPSEQvF2=	NFzXb5pUSU6JRWK=
LXF-289	NYTKcJNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnL2TWM2OD1zMD63PVY4KM7:TR?=	MULTRW5ITVJ?
SW900	M1njSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{f1T2lEPTB;MUCuPFIzQCEQvF2=	Ml\aV2FPT0WU
K-562	NFTwXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXETWM2OD1zMD64N\|k2KM7:TR?=	NUHNfGs2W0GQR1XS
HCC38	NGnSXo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTFyLkm3NVYh\|ryP	Mnv6V2FPT0WU
SF-295	NFXhe5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELtcoZKSzVyPUGwMlk6ODJizszN	MXTTRW5ITVJ?
LB831-BLC	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPOTWM2OD1zMT6yOVU3KM7:TR?=	MljnV2FPT0WU
FTC-133	NXvifnh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vMT2lEPTB;MUGuN\|A5OSEQvF2=	NIL2R3BUSU6JRWK=
HCC1954	M2H3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTFzLkSzOkDPxE1?	M373[3NCVkeHUh?=
GOTO	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTFzLkWyNFYh\|ryP	MWHTRW5ITVJ?
LS-411N	NVHiOZoyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DVTmlEPTB;MUGuOlExOSEQvF2=	NWjHSG1wW0GQR1XS
RPMI-7951	MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXT[WdHUUN3ME2xNU43OzR6IN88US=>	NGPOW3pUSU6JRWK=
NCI-H1299	NWfrVI9TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jaXWlEPTB;MUGuOlY1PyEQvF2=	NUHrO2NGW0GQR1XS
MLMA	M1HPXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTFzLk[5PVch\|ryP	MV;TRW5ITVJ?
MMAC-SF	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTYTWM2OD1zMT63NlUzKM7:TR?=	MYXTRW5ITVJ?
UM-UC-3	MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUT5UoI3UUN3ME2xNU44PDJzIN88US=>	NVXqemlyW0GQR1XS
SCC-9	MlH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4[4U2lEPTB;MUGuPFE2OSEQvF2=	MXvTRW5ITVJ?
HOS	MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULsOZBlUUN3ME2xNU45Pjh\|IN88US=>	MlryV2FPT0WU
OE19	NWPGS2JGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUO0bXE6UUN3ME2xNU46OzZ5IN88US=>	M2DqSXNCVkeHUh?=
Mo-T	NGrTcllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3u0SmlEPTB;MUGuPVU1OSEQvF2=	Mmj3V2FPT0WU
CAMA-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\oTWM2OD1zMj6xOlM{KM7:TR?=	NED2OXFUSU6JRWK=
U-118-MG	M3TlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn61TWM2OD1zMj6yOFQyKM7:TR?=	NIfBTJFUSU6JRWK=
KS-1	M{LpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHUOpNKSzVyPUGyMlI5OzJizszN	NWrURY9EW0GQR1XS
JAR	NUf1XIxET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTF{LkOzOlkh\|ryP	NX;adJpkW0GQR1XS
ABC-1	NF62bYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{[5TGlEPTB;MUKuN\|QyKM7:TR?=	NHzmc\|lUSU6JRWK=
Daoy	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2frVmlEPTB;MUKuOFU1OiEQvF2=	MX7TRW5ITVJ?
C3A	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTF{LkW3PFUh\|ryP	MV;TRW5ITVJ?
GT3TKB	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrOTWM2OD1zMj62N\|I4KM7:TR?=	M3vScXNCVkeHUh?=
DMS-273	NEDD[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTF{Lki2N\|Mh\|ryP	NEDSWGRUSU6JRWK=
G-361	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTF{LkmxNlkh\|ryP	MXjTRW5ITVJ?
RH-18	MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkP4TWM2OD1zMz6yPVYzKM7:TR?=	NWW0d2t3W0GQR1XS
SN12C	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{j1d2lEPTB;MUOuN\|gxQCEQvF2=	Mo[1V2FPT0WU
NCI-H1993	NVfH[JU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTF\|LkSyPFUh\|ryP	NEn6cZJUSU6JRWK=
LOXIMVI	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHr1bolKSzVyPUGzMlYyPTFizszN	NV\rWYM5W0GQR1XS
SK-PN-DW	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\kN4hKSzVyPUGzMlg1OjdizszN	MWrTRW5ITVJ?
KALS-1	M3LPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnYTWM2OD1zMz64OVI2KM7:TR?=	MV7TRW5ITVJ?
LAN-6	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknkTWM2OD1zND6yOVMh\|ryP	MYPTRW5ITVJ?
A549	MorMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1:4WWlEPTB;MUSuOFcyOiEQvF2=	NHHyb5VUSU6JRWK=
RD	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTF2LkS4NVMh\|ryP	NXzrVI17W0GQR1XS
TGBC1TKB	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHyeoRKSzVyPUG0MlY3OTVizszN	M2LJcHNCVkeHUh?=
NCI-H630	Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTF2Lkm0Olch\|ryP	NXzhfFlPW0GQR1XS
MIA-PaCa-2	M1Pj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjYdo1QUUN3ME2xOE46PjlizszN	NHTPTm1USU6JRWK=
NCI-H1755	NXL2WZV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnzTWM2OD1zND65PVU{KM7:TR?=	MWHTRW5ITVJ?
MOLT-4	NH7MT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PmdWlEPTB;MUWuNFQ6PyEQvF2=	MmXaV2FPT0WU
CW-2	M3PRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTF3LkG0NlEh\|ryP	NXPFcGI{W0GQR1XS
COLO-320-HSR	M{TkRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPrTWM2OD1zNT61N\|A4KM7:TR?=	MoCxV2FPT0WU
UMC-11	NWDod5dCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPpTWM2OD1zNT63OVI{KM7:TR?=	NXnMTZZbW0GQR1XS
MCF7	M{HQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7hdXdKSzVyPUG1MlgyPDVizszN	NX3BfXhJW0GQR1XS
NCI-H23	NFLR[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XpTmlEPTB;MUWuPFQ{QCEQvF2=	MWLTRW5ITVJ?
HuCCT1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTF3Lki3OEDPxE1?	M2fUdXNCVkeHUh?=
MPP-89	M3nkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3kTWM2OD1zNT65OFE4KM7:TR?=	M3:xPHNCVkeHUh?=
HT55	M170Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33zeGlEPTB;MUWuPVQ4QCEQvF2=	MkT6V2FPT0WU
no-11	MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7r[mdKSzVyPUG1Mlk3PjNizszN	M2rm[HNCVkeHUh?=
GP5d	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1P0fGlEPTB;MU[uNlE5PyEQvF2=	NVXnRplvW0GQR1XS
BHT-101	MnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXBTWM2OD1zNj6yOFM6KM7:TR?=	NVzPbmlFW0GQR1XS
M059J	MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\OW21KSzVyPUG2MlI5PCEQvF2=	MWHTRW5ITVJ?
D-283MED	NFO2d5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\5dHdjUUN3ME2xOk41OjB7IN88US=>	MmHmV2FPT0WU
BEN	NU\S[lVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\DN2lEPTB;MU[uOVE2PSEQvF2=	MWXTRW5ITVJ?
LB373-MEL-D	NYjZT3h1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoP0TWM2OD1zNj63NlMzKM7:TR?=	NEHofoFUSU6JRWK=
MEL-HO	NX7XbY41T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjFfZlTUUN3ME2xOk45QDV2IN88US=>	NHqxPG9USU6JRWK=
GI-ME-N	NF\aeVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTF4LkmwN\|Ih\|ryP	MkLQV2FPT0WU
RKO	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3mZZVYUUN3ME2xO{4xPzR6IN88US=>	NWHycGl5W0GQR1XS
MZ2-MEL	NFr2d\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITISVFKSzVyPUG3MlE{OyEQvF2=	NY\tcldEW0GQR1XS
NCI-H1573	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzyelBKUUN3ME2xO{4zQDJ4IN88US=>	MmTMV2FPT0WU
NCI-H1581	NIq3OJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrkTWM2OD1zNz60OFEyKM7:TR?=	M3\hdHNCVkeHUh?=
NCI-H747	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTF5LkWyPVch\|ryP	MnywV2FPT0WU
SW1783	MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLFOYNKSzVyPUG3MlY1OTVizszN	MUPTRW5ITVJ?
Calu-6	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLyTWM2OD1zNz62O\|gzKM7:TR?=	MlLJV2FPT0WU
SF268	M1LGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFv5doZKSzVyPUG3MlY6PjlizszN	MmmyV2FPT0WU
ES8	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTF5Lki1PVMh\|ryP	Mn;GV2FPT0WU
KM-H2	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFr2WmNKSzVyPUG3Mlk1OTFizszN	MXTTRW5ITVJ?
D-502MG	MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fQcmlEPTB;MUeuPVgxQCEQvF2=	M3v5fnNCVkeHUh?=
HLE	M2PUfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPNWVl{UUN3ME2xPE4{OTR6IN88US=>	NFrOSlZUSU6JRWK=
SW982	NX6zenZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rSNGlEPTB;MUiuOFA4PSEQvF2=	NEnpfJZUSU6JRWK=
MDA-MB-361	M3LEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTF6LkW1PFgh\|ryP	MWnTRW5ITVJ?
NCI-H1563	NULZOphUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWW4bpZ3UUN3ME2xPE44OTJ2IN88US=>	MYXTRW5ITVJ?
MFE-280	NGT6PIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPwTWM2OD1zOD63Nlk{KM7:TR?=	M3Lhc3NCVkeHUh?=
U251	NHHwSZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XBcWlEPTB;MUiuO\|M1PyEQvF2=	NXHtVnBXW0GQR1XS
KNS-42	NWnvbZhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWL0OpJOUUN3ME2xPE45ODF3IN88US=>	NV;ydJcyW0GQR1XS
U-266	MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vxdGlEPTB;MUiuPFY1QSEQvF2=	M3HZU3NCVkeHUh?=
OVCAR-8	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvIU5F{UUN3ME2xPE46Ojd4IN88US=>	NH\jd3FUSU6JRWK=
MFH-ino	NFi2VXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXiOIo{UUN3ME2xPE46PjZ7IN88US=>	NX;QRYN1W0GQR1XS
D-263MG	NYHWUGJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\1dGlEPTB;MUmuNFE4OiEQvF2=	MUTTRW5ITVJ?
NCI-H1437	NYXhe4R4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LIW2lEPTB;MUmuNFQ3PyEQvF2=	NUO3fWtzW0GQR1XS
NCI-H1048	NH;2TFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4q4dGlEPTB;MUmuNlMzPiEQvF2=	NWfyTWhbW0GQR1XS
NCI-H446	NFrPUHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTF7LkO1PFkh\|ryP	MoOxV2FPT0WU
NCI-N87	MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH6xVHpKSzVyPUG5MlU6QTJizszN	M4\3R3NCVkeHUh?=
WM-115	NVTmOnN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTF7Lk[3O\|Qh\|ryP	NHO0XJlUSU6JRWK=
HuH-7	NFvodWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\iWmlEPTB;MUmuO\|QzOSEQvF2=	NYXwT2NZW0GQR1XS
NCI-H650	M2\2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTF7Lke1NFgh\|ryP	NILKcXlUSU6JRWK=
TYK-nu	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvMS\|kzUUN3ME2xPU45Ozd6IN88US=>	M2LqeHNCVkeHUh?=
Becker	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTF7Lki1OFch\|ryP	MXHTRW5ITVJ?
BB49-HNC	NFjJOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfseYlzUUN3ME2xPU46OiEQvF2=	MmjpV2FPT0WU
HGC-27	NHHqbXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETVW2xKSzVyPUKwMlE{QTRizszN	M4PQOnNCVkeHUh?=
SiHa	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{Syd2lEPTB;MkCuN\|cyOiEQvF2=	MWDTRW5ITVJ?
LB2518-MEL	MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3ES2UxUUN3ME2yNE4{PzN7IN88US=>	MWrTRW5ITVJ?
TE-5	NHj1SHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTJyLke0PFIh\|ryP	NFO0bnRUSU6JRWK=
IST-SL1	M{TKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIntbGRKSzVyPUKwMlc5PzlizszN	M2q2Z3NCVkeHUh?=
A375	M{j3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjEXJM6UUN3ME2yNU4xPTZ5IN88US=>	MYTTRW5ITVJ?
MC116	M1XPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{KxVmlEPTB;MkGuNFczOyEQvF2=	Mk\5V2FPT0WU
GI-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jYPGlEPTB;MkGuNVch\|ryP	M1\NNXNCVkeHUh?=
HOP-62	NUHidGxwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTJzLkK3PFQh\|ryP	MXzTRW5ITVJ?
PA-1	NHXsT2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTJzLkK3PFch\|ryP	M1\GTXNCVkeHUh?=
HT	NHrnd5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLCTWM2OD1{MT60N\|MyKM7:TR?=	MmPIV2FPT0WU
HUTU-80	M1HSdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUOyZ2cyUUN3ME2yNU41OzN4IN88US=>	MmDvV2FPT0WU
NCI-H1975	NF;6NGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3nEOmlEPTB;MkGuOFYyKM7:TR?=	M4nIfHNCVkeHUh?=
GAK	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULiSXo6UUN3ME2yNU41QTlizszN	MVvTRW5ITVJ?
SK-N-AS	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TPOGlEPTB;MkGuOVYyQSEQvF2=	M1qwfnNCVkeHUh?=
OE33	NU[0e3Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NES2RlhKSzVyPUKxMlYxPDZizszN	MnjsV2FPT0WU
YKG-1	NEezbJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWX3RWd{UUN3ME2yNU43PTR3IN88US=>	MVPTRW5ITVJ?
CAL-85	M2TOXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2DySmlEPTB;MkGuPVMxPSEQvF2=	MnTEV2FPT0WU
NCI-H2347	NWHmS2NmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;RTWM2OD1{MT65OFI5KM7:TR?=	NXSyO3pXW0GQR1XS
PANC-08-13	M{jIb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTJ{LkCxNVkh\|ryP	MoHLV2FPT0WU
SK-N-FI	Mkn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn6yTWM2OD1{Mj6zNFc1KM7:TR?=	NX\VfmdTW0GQR1XS
NEC8	NHHj[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPDTWM2OD1{Mj61NFc5KM7:TR?=	Ml7NV2FPT0WU
AN3-CA	NETld5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLMV4llUUN3ME2yNk43ODh2IN88US=>	NFnVOIhUSU6JRWK=
HuO9	M3O1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrHNXVKSzVyPUKyMlc{QTZizszN	NX\R[2hYW0GQR1XS
COLO-800	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTPTWM2OD1{Mj63OlU{KM7:TR?=	MWXTRW5ITVJ?
HT-29	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXyzU\|NkUUN3ME2yNk45QDJ\|IN88US=>	M3;CenNCVkeHUh?=
OC-314	Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTJ{Lki4OFUh\|ryP	MXXTRW5ITVJ?
G-401	NVvRXGJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHMXWR7UUN3ME2yN{4xPDZ{IN88US=>	M1PCTnNCVkeHUh?=
Saos-2	M4\BU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljkTWM2OD1{Mz61NVgzKM7:TR?=	M1LUT3NCVkeHUh?=
UACC-62	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4L3b2lEPTB;MkOuOVg{OyEQvF2=	MV7TRW5ITVJ?
D-247MG	M17tRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3qxb2lEPTB;MkOuO\|k{QSEQvF2=	NF\sOotUSU6JRWK=
COLO-741	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\CenBKSzVyPUKzMlk2PjVizszN	MlTyV2FPT0WU
ES3	NFLCSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\I[ldiUUN3ME2yOE4xODJ\|IN88US=>	MXPTRW5ITVJ?
LNCaP-Clone-FGC	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nBdWlEPTB;MkSuNFIyOSEQvF2=	M3nvT3NCVkeHUh?=
SW1710	MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rJN2lEPTB;MkSuNVUxPiEQvF2=	M2H4OnNCVkeHUh?=
LU-99A	NWHjcVJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFK5WYdKSzVyPUK0MlE5PDFizszN	M3\CT3NCVkeHUh?=
HOP-92	MkHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHh[293UUN3ME2yOE44OjVizszN	M{KwZnNCVkeHUh?=
LS-123	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTJ2Lkm2NVQh\|ryP	M3LMUHNCVkeHUh?=
T84	NIPldpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLUXpRTUUN3ME2yOE46PzZ3IN88US=>	M1Xrb3NCVkeHUh?=
HCT-116	MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TCNmlEPTB;MkWuOFE5PiEQvF2=	MnHZV2FPT0WU
M14	MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHBTWM2OD1{NT60OFQ4KM7:TR?=	NGj5UW1USU6JRWK=
OCUB-M	NVrETWg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XTWmlEPTB;MkWuOFQ2PiEQvF2=	MlTyV2FPT0WU
MKN45	M4LEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fJeGlEPTB;MkWuOlMyPSEQvF2=	Mm\LV2FPT0WU
LCLC-97TM1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHJTWM2OD1{NT63Nlg2KM7:TR?=	NILCbY9USU6JRWK=
RVH-421	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17XNWlEPTB;MkWuPFE3OSEQvF2=	NHPRdWxUSU6JRWK=
NKS-81-FD	MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2i2OmlEPTB;MkWuPVAzOSEQvF2=	NHnnR3FUSU6JRWK=
NCI-H596	NXHabJYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFWzV\|JKSzVyPUK2MlA1QDdizszN	M{XHfXNCVkeHUh?=
GB-1	MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LhSmlEPTB;Mk[uNVg4QSEQvF2=	NHyweZJUSU6JRWK=
ZR-75-30	MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHoTWM2OD1{Nj6yNlk4KM7:TR?=	NUn6V\|V3W0GQR1XS
U-2-OS	NYnlUWpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUn0T5MxUUN3ME2yOk4{PzV5IN88US=>	MXrTRW5ITVJ?
HuP-T3	NYfKTVJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTMW25KSzVyPUK2MlYyODJizszN	MlrQV2FPT0WU
MOLT-16	Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVi3XVlRUUN3ME2yOk43OTZ4IN88US=>	MXjTRW5ITVJ?
U-87-MG	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTJ4Lke0N\|gh\|ryP	M4XKenNCVkeHUh?=
8505C	MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPHenpKSzVyPUK2MlkyOjZizszN	MXXTRW5ITVJ?
SK-MEL-3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTJ4Lkm4Nlgh\|ryP	MoTyV2FPT0WU
COLO-824	MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTJ5LkKxPVUh\|ryP	MX7TRW5ITVJ?
EW-1	NVHoeWVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\jXmlEPTB;MkeuN\|U2PCEQvF2=	MWfTRW5ITVJ?
UACC-257	M{LCNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnmTWM2OD1{Nz6zPFA1KM7:TR?=	MlTCV2FPT0WU
Hs-578-T	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXuPFNKSzVyPUK3MlUzQTlizszN	NGjsOpVUSU6JRWK=
UACC-893	MoPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;WW2lEPTB;MkeuOlY{OSEQvF2=	MVLTRW5ITVJ?
MHH-NB-11	NELpUnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17FPGlEPTB;MkeuPFAxPyEQvF2=	NXS3PZZvW0GQR1XS
KYSE-410	NVrySolZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17COmlEPTB;MkiuNlc4QSEQvF2=	MlLXV2FPT0WU
SF126	M2fVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTJ6Lke0N\|Uh\|ryP	NHTkdHBUSU6JRWK=
HT-144	MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn2wTWM2OD1{OT6zN\|YzKM7:TR?=	NXfNfGhNW0GQR1XS
SW1573	M1HNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH:0NVBKSzVyPUK5MlM2ODlizszN	NH3hb4FUSU6JRWK=
SW620	NGLIU3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTJ7LkO2OFEh\|ryP	M17BcHNCVkeHUh?=
SCH	NF7jfoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{P2[WlEPTB;MkmuPFg{OSEQvF2=	MmDnV2FPT0WU
EW-22	NHvOSmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PWWmlEPTB;M{CuNVk3QSEQvF2=	MVLTRW5ITVJ?
H4	MmfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrvO4FjUUN3ME2zNE41PjV2IN88US=>	NUj6TW9oW0GQR1XS
CAS-1	NHvtbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjMTYtjUUN3ME2zNE44QDV7IN88US=>	NVfYOZhMW0GQR1XS
MG-63	NV6xcldUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTNyLki0O\|gh\|ryP	MkizV2FPT0WU
MDA-MB-415	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFi5W3dKSzVyPUOxMlE4PTNizszN	MkfMV2FPT0WU
NCI-H1395	NVHC[W1kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTNzLkKzNlgh\|ryP	NH;h[WlUSU6JRWK=
Ca-Ski	NIDaeGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXRVmtPUUN3ME2zNU4{OTd5IN88US=>	M{XwbnNCVkeHUh?=
BxPC-3	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTNzLkO3Nlkh\|ryP	MVnTRW5ITVJ?
A3-KAW	MmSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTNzLkS0O\|Eh\|ryP	NX;Z[GF1W0GQR1XS
T-24	MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIG4XFVKSzVyPUOxMlc{PjJizszN	MmXxV2FPT0WU
NCI-H2029	MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfKWWc2UUN3ME2zNU44PzZ3IN88US=>	MXXTRW5ITVJ?
YAPC	M2TyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPLTWM2OD1\|Mj6wOFA4KM7:TR?=	M1TjdnNCVkeHUh?=
SK-MEL-2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVj3[YVMUUN3ME2zNk4xPTJizszN	MXrTRW5ITVJ?
LS-513	MnfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTN{LkGxPFch\|ryP	MVHTRW5ITVJ?
AsPC-1	NXLOWWdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTR[VF1UUN3ME2zNk4{PjB3IN88US=>	M176VnNCVkeHUh?=
KYSE-150	M3e2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTN{LkO3O\|Mh\|ryP	Mof2V2FPT0WU
NCI-H520	NGC3SmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M333TGlEPTB;M{KuOFQ5OiEQvF2=	MV7TRW5ITVJ?
JEG-3	M3nWUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;aTWM2OD1\|Mz6wPVcyKM7:TR?=	MXrTRW5ITVJ?
GMS-10	NUn1cXJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTN\|LkOwNFQh\|ryP	NHzBbI5USU6JRWK=
HT-1080	NIDBfIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2XXcmlEPTB;M{OuN\|kh\|ryP	NUnmRmlZW0GQR1XS
NCI-H1651	NEPyXHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGK5NmlKSzVyPUOzMlM6PiEQvF2=	NEnnSGtUSU6JRWK=
NCI-H2122	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTN\|LkW1O\|Qh\|ryP	MlPuV2FPT0WU
ES5	NYnM[4Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnBbo5KSzVyPUOzMlczQTJizszN	M{e4Z3NCVkeHUh?=
8305C	NXz1VXB6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjsTWM2OD1\|Mz65PVM4KM7:TR?=	MnnEV2FPT0WU
KM12	M{HHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHnTWM2OD1\|ND6wOFc5KM7:TR?=	M{mwT3NCVkeHUh?=
HCT-15	NHfUTnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY[4[otJUUN3ME2zOE4yOjdizszN	M{X4V3NCVkeHUh?=
OVCAR-5	NVjPeXQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvXNGN3UUN3ME2zOE4zOTh{IN88US=>	NE\1[Y9USU6JRWK=
NCI-H2291	NITKT5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXITWM2OD1\|ND6yOFczKM7:TR?=	NF7ROpBUSU6JRWK=
CP50-MEL-B	M2\MPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTJTWM2OD1\|ND62OVkzKM7:TR?=	NFfQ[XlUSU6JRWK=
C-33-A	MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\TTWlEPTB;M{SuOlg2PyEQvF2=	NFThOXJUSU6JRWK=
NCI-H2452	M4HpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF75TFBKSzVyPUO0Mlc5QDJizszN	NE\MOmdUSU6JRWK=
MDA-MB-157	M2fxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrDdIVpUUN3ME2zOE45OTl\|IN88US=>	MYfTRW5ITVJ?
LN-405	NVnyd2FWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\IcpRxUUN3ME2zOU41OzB6IN88US=>	M3qyZXNCVkeHUh?=
MDA-MB-231	M2TxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nZV2lEPTB;M{WuOVA2PCEQvF2=	NWXvO4lZW0GQR1XS
EW-24	NGDkbo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DKSmlEPTB;M{WuOlM{PSEQvF2=	NVHtNI9NW0GQR1XS
MKN28	NFP4XGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{G5[WlEPTB;M{WuPFI{PiEQvF2=	M17RPXNCVkeHUh?=
KINGS-1	M4\vfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{KwUWlEPTB;M{WuPFQ{PCEQvF2=	MWnTRW5ITVJ?
LC-2-ad	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\vTWM2OD1\|Nj62PVkh\|ryP	NV3aVnRSW0GQR1XS
IGR-1	M1TsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPXV3Z4UUN3ME2zOk44ODd3IN88US=>	Mn:1V2FPT0WU
SW626	M3v1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DUT2lEPTB;M{euNFQyPyEQvF2=	MnTkV2FPT0WU
ONS-76	M{fxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TpbGlEPTB;M{euNVMxQSEQvF2=	MYTTRW5ITVJ?
T98G	M4Dtdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLoZZBKSzVyPUO3Mlg3OzVizszN	NH33bHBUSU6JRWK=
NB14	M3ewUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTmWopbUUN3ME2zPE41PTR2IN88US=>	MXLTRW5ITVJ?
D-423MG	Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHH0SVJKSzVyPUO4MlQ5PjlizszN	NFvibIxUSU6JRWK=
NCI-H510A	M2PnVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\WUWRKSzVyPUO4MlY1PTFizszN	MmPlV2FPT0WU
NMC-G1	NX31ZpJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4KwOGlEPTB;M{iuO\|IzOiEQvF2=	MoTZV2FPT0WU
SW948	MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWH2NGhuUUN3ME2zPE45QTR7IN88US=>	MVnTRW5ITVJ?
MFM-223	NWfQZXpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml6wTWM2OD1\|OD65OFMyKM7:TR?=	NXfCRnRUW0GQR1XS
PAN1	MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWK5S4I{UUN3ME2zPE46QTF7IN88US=>	NITBTY1USU6JRWK=
MZ7-mel	NVO1[YUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HnNWlEPTB;M{muNVE6QSEQvF2=	NF3BTo9USU6JRWK=
COLO-679	M2XZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLpZ2ZKSzVyPUO5Mlk4ODhizszN	MX7TRW5ITVJ?
SW872	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;rTWM2OD12MD6yNFMyKM7:TR?=	NX;5XI1RW0GQR1XS
HT-1197	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3S2U2lEPTB;NECuNlg3QSEQvF2=	M3zyVXNCVkeHUh?=
ES6	NIrEcnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rJOWlEPTB;NECuOFU2OiEQvF2=	Mn3HV2FPT0WU
SNU-387	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTRyLkiyN\|gh\|ryP	NWSwSGF4W0GQR1XS
T47D	MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DrSmlEPTB;NEGuNFE6OiEQvF2=	NV\yWGdFW0GQR1XS
G-402	NYPM[2N7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTRzLkC4NFkh\|ryP	NIHhVllUSU6JRWK=
MZ1-PC	MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjCTWM2OD12MT64NUDPxE1?	MmjkV2FPT0WU
SW1417	NUjKVmc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnKxTWM2OD12Mj6zNFMh\|ryP	NWG4bmxuW0GQR1XS
RERF-LC-MS	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkGwTWM2OD12Mj61NFg4KM7:TR?=	MXLTRW5ITVJ?
SF539	NVXGfJE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1i4OGlEPTB;NEKuOVUzQSEQvF2=	M3rYcnNCVkeHUh?=
ESS-1	NXu5PGhOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjPcI1FUUN3ME20N{42PTV6IN88US=>	MWPTRW5ITVJ?
RO82-W-1	NE\NWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorLTWM2OD12Mz62NVU{KM7:TR?=	MVTTRW5ITVJ?
S-117	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\xZYRKSzVyPUSzMlY6PThizszN	MWTTRW5ITVJ?
SW756	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEf6ZmZKSzVyPUSzMlgzPDJizszN	NUfLdJZMW0GQR1XS
CP66-MEL	NHqycmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLuOpZoUUN3ME20OU44OTR\|IN88US=>	Ml;FV2FPT0WU
H-EMC-SS	M1jmUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LTb2lEPTB;NEWuO\|Y6OyEQvF2=	M4izVHNCVkeHUh?=
NCI-H2052	NV7mbW57T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrvNXMyUUN3ME20OU46ODJ5IN88US=>	M3z2NXNCVkeHUh?=
SW684	MlH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfuXXNlUUN3ME20O{4xODhzIN88US=>	MXTTRW5ITVJ?
HCC1569	Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfCVGpKSzVyPUS3MlE3PThizszN	NHz4OFVUSU6JRWK=
KGN	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2K3RWlEPTB;NEeuN\|MyOSEQvF2=	MWDTRW5ITVJ?
LCLC-103H	MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3u4e2lEPTB;NEeuOFQxPCEQvF2=	NHHRbFJUSU6JRWK=
SW780	NWPNTHVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHvVZlXUUN3ME20O{43OzVzIN88US=>	NFznOo9USU6JRWK=
NCI-H1703	NEnSemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTR6LkOzOVIh\|ryP	M3vSdXNCVkeHUh?=
HCC1395	NX\zVFI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnkPVZKSzVyPUS4Mlc1OzJizszN	NFeyNmpUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-EGFR / phospho-ERK / phospho-SRC / phospho-AKT; PubMed: 22586683 Cancer Discov Effect of overexpressing CRKL on phosphorylation levels of EGFR, ERK, AKT and SRC in response to gefitinib. HCC827 cells expressing a control vector or CRKL were exposed to gefitinib at indicated concentrations for 6 h and cell lysates were collected for immunoblotting with indicated specific antibodies. Cyclin D1/ p16 / p27 / pRb; PubMed: 18559346 J Biol Chem levels of phosphorylated and total EGFR, IGF-1R, Akt, ERK1/2, and Rb and levels of cyclin D1, p27, p16, and actin following 6- or 16-h treatment of A431 cells with combinations of 1 or 3 μm gefitinib and 3 μm NVP-ADW742. Data are representative of two independent experiments. uc-caspase-9 / c-caspase-9 / uc-caspase-3 / c-caspase-3 / uc-PARP / PARP; PubMed: 23102728 Mol Oncol Apoptosis resulting from combined treatment with gefitinib and an MEK inhibitor. (A) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/wt and PC‐9/gef B4 cells. (B) Apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/wt and PC‐9/gef B4 cells. (C) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/gefE3 and PC‐9/gefE7 cells. (D) apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/gefE3 and PC‐9/gefE7 cells. PPAR-γ; PubMed: 23409107 PLoS One Fold increase relative to control was determined after normalization with β-actin as external loading control.	22586683 18559346 23102728 23409107
Immunofluorescence	EGFR / LC3; PubMed: 31196210 J Exp Clin Cancer Res H157 and H1299 cells were treated with gefitinib, or curcumin alone, or gefitinib plus curcumin at indicated concentration for 48 h and then were fixed with methanol, immunostained with anti-EGFR (green), anti-LC3 (red), and DAPI (blue), and analyzed by confocal microscopy to determine the intracellular locations of EGFR and LC3. PPAR-γ; PubMed: 23409107 PLoS One Upregulation and nuclear accumulation of PPARγ following treatment with gefitinib (24 hs). p-EGFR / β-catenin; PubMed: 23461856 FEBS J In untreated CNE2 cells, β-catenin was located in cytoplasmic membranes and cytoplasm. Treatment with EGF (50 ng/mL) resulted in increased β-catenin nuclear staining, which was reversed by either gefitinib (1 μM) or LY294002 (15 μM).	31196210 23409107 23461856
Growth inhibition assay	GI50; PubMed: 23409107 PLoS One Dose-response of bladder cancer cell lines to EGFR inhibitor (gefitinib). The GI50 value was defined as the mean concentration of drug that generates 50% of growth inhibition as compared to controls.	23409107

In vivo

Gefitinib (100 mg/kg) improves the anti-tumor effect of radiotherapy in LoVo tumor xenografts. ^[3] Gefitinib treatment of nude mice bearing established human GEO colon cancer xenografts reveals a reversible dose-dependent inhibition of tumor growth because GEO tumors resumes the growth rate of controls at the end of the treatment. ^[4]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: NR6, NR6M and NR6W cells
Concentrations: 0-2 μM
Incubation Time: 72 hours
Method: Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay.
(Only for Reference)

Animal Research:^[3]

- Collapse

Animal Models: Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells.
Formulation: 0.5% polysorbate
Dosages: 100 mg/kg
Administration: Once daily by oral administration (0.1 mL/10 g body weight) for 14 days
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	89 mg/mL (199.14 mM)
	Ethanol	4 mg/mL (8.95 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% CMC Na For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Gefitinib (ZD1839) SDF

Molecular Weight	446.90
Formula	C₂₂H₂₄ClFN₄O₃
CAS No.	184475-35-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	COC1=C(OCCCN2CCOCC2)C=C3C(=NC=NC3=C1)NC4=CC=C(F)C(=C4)Cl

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03292133	Recruiting	Drug: EGF816\|Drug: Gefitinib	Lung Cancer	Massachusetts General Hospital\|Novartis	October 31 2017	Phase 2
NCT03122717	Recruiting	Drug: Gefitinib\|Drug: Osimertinib	Non-Small Cell Lung Cancer	Dana-Farber Cancer Institute\|AstraZeneca	May 9 2017	Phase 1\|Phase 2
NCT02932345	Completed	--	EGFR Mutation Positive Advanced Non-small-cell Lung Cancer	AstraZeneca	October 31 2016	--
NCT02824458	Recruiting	Drug: Apatinib\|Drug: Gefitinib\|Drug: Placebo	EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors	Sun Yat-sen University	June 2016	Phase 3
NCT02804100	Unknown status	--	Carcinoma Non-Small-Cell Lung\|Bronchial Neoplasms\|Carcinoma Bronchogenic\|Lung Diseases\|Lung Neoplasms	Wenzhou Medical University	May 2016	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I try to dissolve Gefitinib (ZD1839) in 0.5% methylcellulose+0.2% Tween 80 for in vivo experiments. However, when I prepare the mixture, it forms precipitates. Exists another way to dissolve completely the compound?
Answer:
S1025 can be dissovled in both 5% DMSO+corn oil and 5% DMSO+30% PEG 300+5% Tween 80+ddH2O at 2.5 mg/ml clearly. It dissolves in DMSO not readily, please sonicate and warm it in water bath at about 45 degree, and dissolve it clearly first. Then add other solvent.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Pan EGFR Inhibitor

AZD8931 (Sapitinib) : Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.
Most Potent EGFR Inhibitor

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Related EGFR Products

Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Choose Your Country or Region

By Signaling Pathways

By product type

Gefitinib (ZD1839)